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Oligodendrocyte (OL) loss contributes to the functional deficits underlying 
diseases with a demyelinating component (Gajjar et al., 1997; Miller et al., 2002). 
Remyelination can restore these deficits (Duncan et al., 2009). Chapter 1 is an 
introduction to de- and re-myelination thus providing the necessary background 
information for consideration in subsequent chapters. Ethidium bromide (EB) has 
been extensively used in the rat and cat as a model of spinal cord demyelination. 
However, this lesion has not been addressed in the adult mouse. Therefore, 
Chapters 2 and 3 characterize a model of chronic EB-induced spinal cord 
demyelination in the mouse which can be assessed behaviorally and 
electrophysiologically.  
MicroRNAs (miRNAs) possess both cell type- and differentiation stage-
specific expression patterns (Lau et al., 2008). In oligodendrocytes (OLs), 
miRNAs regulate development and differentiation in vivo and in vitro, respectively 
(Lin et al., 2009; Zhao et al., 2010 and Dugas et al., 2010). However, it is unclear 
whether miRNAs involved in remyelination are distinct from those observed 
during normal myelination / development. Treatment of adult mice with the  
  viii   
copper chelator cuprizone demyelinates specific brain regions which remyelinate 
following cuprizone cessation (Torkildsen et al., 2008). Therefore, Chapter 4 
focuses on the role of oligodendroglial-specific miRNAs in cuprizone-induced de- 
and re-myelination.  
Lastly, Chapter 5 summarizes all of the data provided herein with an 
emphasis on clinical significance and therapeutic potential. 
 ix  
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Preface. Oligodendrocytes (OLs) are the sole source of myelin in the central 
nervous system (CNS). Their primary role is to form the myelin sheath, a 
dielectric structure composed of multiple tightly wrapped layers necessary for 
proper conduction of action potentials from the axon hillock to its terminus (Bradl 
and Lassmann, 2010). However, they also serve as a protective layer and 
provide trophic support to CNS axons (Nave, 2010). OLs promote optimal 
conduction velocity and intensity, both critical to maintaining efficient propagation 
of action potentials over long distances which can span up to several meters 
(Baumann and Pham-Dinh, 2001). 
 
Oligodendrocyte Biology  
 
A single OL extends multiple processes which can then myelinate tens to 
hundreds of axons. Therefore, within white matter structures (groups of highly 
myelinated axons), many OLs are present in a relatively even distribution along 
the axonal tract providing the myelin, protection and trophic support required for 
communication between grey matter regions (groups of neuronal cell bodies).         
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OL development. OLs are the last cells to develop in the CNS with the 
myelination of axons beginning during the second trimester in humans (Poduslo 
and Jang, 1984) and at postnatal day 0 in rodents (Semple et al., 2013). 
Myelination peaks soon after birth slowly tapering off throughout adolescence 
and adulthood with myelin levels beginning to decline at approximately age 40 in 
humans and 8-10 weeks in rodents (Bartzokis et al., 2010). During embryonic 
neural tube formation, oligodendrocyte progenitors (OPs) begin to arise primarily 
in the ventral spinal cord (Timsit et al., 1995) with a sub-population arising from 
the dorsal spinal cord (Qiang et al., 2010) as well as in the third ventricle (Gao 
and Miller, 2006) and begin to proliferate in high numbers. Using in vitro 
approaches, we now understand that newly generated OPs are generated under 
the mitogenic control of insulin-like growth factor 1 (IGF-1), fibroblast growth 
factor 2 (FGF2) and platelet derived growth factor alpha (PDGFα) secreted from 
neurons and astrocytes (Scolding et al., 1995; Frederick and Wood, 2004). This 
has been confirmed as intraventricular FGF2 administration in both pups and 
adult mice enhanced the production of OPs throughout the subventricular zone 
(SVZ) and within both the dorsal- (dSVZ) and inner-subventricular zones (lSVZ; 
Azim et al., 2012). They are identified in vivo by the immunohistochemical (IHC) 
and promoter based reporter expression of the transcription factor Olig2, the 
growth factor receptor platelet derived growth factor receptor alpha (PDGFRα), 
the proteoglycan NG2, 2’,3’ cyclic nucleotide phosphodiesterase (CNPase) and 
the surface ganglioside A2B5 (Baumann and Pham-Dinh, 2001). Moreover, the 
expression of each of these OP-specific markers has also been demonstrated in 
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vitro. Once formed, newly generated OPs migrate throughout CNS white matter 
directed by N-methyl-d-aspartic acid (NMDA) receptor (NMDAR) signaling (Xiao 
et al., 2013). Migration ceases for spinal-derived OPs when they terminate at an 
axonal segment lacking myelin within the brain or spinal cord. OPs which arise 
from the 3rd ventricle follow a separate migratory route ultimately terminating at 
and myelinating the optic nerve (Ono et al., 1997). The ventral OP differentiation 
signaling pathway is sonic hedgehog (Shh) dependent while the dorsal pathway 
is not (Mitew et al., 2013; Ortega et al., 2013). Moreover, not all OPs form 
oligodendrocytes as some form astrocytes which occurs primarily in grey matter 
(Temple and Raff, 1985) while a small subset of OPs do not differentiate during 
normal development and remain evenly distributed throughout the grey and white 
matter in an immature mitotically competent state (Gensert and Goldman, 1997). 
The role of OPs which persist throughout adulthood is addressed in more detail 
in Chapter 1, Remyelination. Once at their terminal location, myelinating OPs 
begin to mature into pre-myelinating OLs which express differentiation markers 
galactosylceramidase (GalC) and the sulfatides O4 and O1 both in vivo and in 
vitro (Levine et al., 2001). Differentiation into myelinating OLs has been 
described in vitro to be under the transcriptional control of Olig2, Olig1, Nkx2.2 
(Joubert et al., 2010) and ying yang 1 (YY1; He and Casaccia-Bonnefil, 2008) as 
each of these studies co-localized expression of oligodendroglial specific 
markers with transcription factor expression. As a last step in myelination, the 
myelin compaction proteins proteolipid protein (PLP), myelin basic protein (MBP), 
myelin associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein 
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(MOG) and CNPase begin to increase their expression (Huang et al., 2013). This 
has also been confirmed in vitro as myelin compaction protein expression and 
mRNA levels increase concomitant with differentiation even in the absence of 
axons (Armstrong et al., 1990; Joubert et al., 2010).  
 
Myelin composition. Mature myelin consists of tightly wrapped layers of lipid 
membrane densely integrated with myelin compaction proteins PLP, MBP and to 
a lesser extent MAG, MOG and CNPase (Morell and Quarles, 1999). The 
regulation and maintenance of myelin is a dynamic process as even small 
disruptions in mature myelin proteins can result in substantial axonal dysfunction 
(Iester et al., 1997). It has been suggested that optimal myelination levels can be 
promoted by skill training and physical activity (Sampaio-Baptista et al., 2013) 
and by maintaining a healthy diet (Tomasch, 1961).    
 
Biomechanics of myelin sheath formation. When the elongating process of a 
maturing OL reaches an unmyelinated axon, a process unfolds beginning with 
rapid cell adhesion molecule-induced myelin protein synthesis, axon wrapping, 
compaction and finally termination of the myelination process. Initially,  integrin 
receptors on the developing OL processes are activated by axonal integrin 
receptors when the axoglial connection is formed resulting in the release and 
translation of pre-transcribed MBP mRNA from RNA binding proteins at the site 
of myelination, distal to the OL soma thus explaining how myelin protein 
synthesis occurs so soon after axonal contact (Laursen et al., 2011). The newly 
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formed axoglial association is further strengthened by local release of both 
glutamate and action potential-induced adenosine triphosphate (ATP) release 
which is recognized by NMDA receptors and purinergic receptors on the OL, 
respectively (Matute, 2011; Wake et al., 2011). Both cell adhesion molecule- and 
glutamate/ATP-induced molecular cascades converge on the Fyn kinase, 
increasing its activity thus driving OL process elongation (Klein et al., 2002).              
 
The process of myelin wrapping remains incompletely elucidated in the CNS. 
However, in the peripheral nervous system (PNS), Schwann cell myelin wrapping 
has been described in much more detail. From a molecular standpoint, the 
wrapping of peripheral axons by Schwann cell myelin requires the signal 
transduction protein neural Wiskott-Aldrich syndrome protein (N-WASP) which 
interacts with activated cell surface receptors ultimately driving the cytoskeletal 
actin polymerization necessary for membrane elongation and myelination (Novak 
et al., 2011). In genetically engineered mice lacking N-WASP, ultrastructural 
analysis revealed that peripheral myelin was morphological abnormal with few 
instances of tightly wound myelin arranged in uniform layers (Novak et al., 2011).  
What is understood about OL myelin wrapping is that lamellipodia formation 
occurs resembling Schwann cell myelination. Moreover, this process is driven by 
actin polymerization and is mediated by Wiskott-Aldrich syndrome protein family 
verprolin homologous (WAVE) proteins during myelination (Bauer et al., 2009). 
Myelin wrapping must occur until the appropriate thickness of myelin is attained 
with the optimal myelin sheath thickness being directly proportional to the 
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diameter of an axon (i.e. larger diameter axons require thicker myelin sheaths) 
and this proportional relationship has been termed the G-ration (Franklin and 
ffrench-Constant, 2008). G-ratios allow for experimental quantification of myelin 
status and thickness and can be a useful diagnostic tool to assess the overall 
functional capacity of white matter.  
 
Following myelin wrapping is myelin compaction which involves certain proteins 
and glycoproteins present in the myelin sheath but this process is still not 
completely understood. However, it is clear that not all mature myelin proteins 
are necessary for compaction to occur. PLP null mutants still display myelin 
compaction (Bakhti et al., 2013) while MBP null mutants exhibit a clear loss of 
compact myelin resulting in substantial dysfunction (Readhead and Hood, 1990). 
There is a loss of the negatively charged oligosaccharide-induced electrostatic 
repulsion which normally prevents bilayer-bilayer interaction. This allows for 
multiple layers of OL process lipid bilayers to come into close enough proximity 
with adjacent bilayers to allow myelin protein interactions/binding to occur (Bakhti 
et al., 2013).  
 
Myelin internode formation and saltatory conduction. The presence of a myelin 
sheath was first described by the German pathologist and anatomist Rudolf 
Virchow (Virchow, 1854). A decade later, the French pathologist Louis-Antoine 
Ranvier identified gaps in the myelin sheath initially described by Virchow and 
termed the structures nodes (gaps) of Ranvier. Now, more than a century 
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following Virchow and Ranvier’s discovery of intermodal myelin, we currently 
understand that internodal myelin formation on axons is accompanied by 
changes in axonal membrane ion channel distribution which is crucial to the 
proper conduction of action potentials along the axon. Normally, an unmyelinated 
axon has voltage gated sodium and potassium channels, Na+/K+ ATPases and 
Na+/Ca2+ exchangers evenly distributed along its membrane (England et al., 
1990). As the axoglial association forms and OLs begin to wrap an axon with 
segments of myelin, the ion channels redistribute within the axonal membrane 
clustering at the nodes of Ranvier (Black et al., 1990).  
 
Not all axons are myelinated. The small diameter unmyelinated A-delta and C-
fibers within ventral spinal white matter that convey pain/temperature sensory 
information do not myelinate. These fibers conduct action potentials at a much 
slower rate than do larger diameter myelinated fibers (Sotnikov, 2003). 
Therefore, myelination seems to be crucial to action potential conduction velocity 
which becomes increasingly important when considering that some large 
diameter efferent axons must travel several meters before terminating on a lower 
motor neuron in the anterior grey horn of the spinal cord. Once an axon has been 
properly myelinated with compact layers of myelin at the appropriate G-ratio, 
internode formation has occurred and ion channels have clustered at the nodes 
of Ranvier, rapid and efficient conduction of action potentials by myelinated fibers 
termed saltatory conduction can now take place. Saltatory conduction prevents 
the decay of action potential intensity as action potentials jump from node to 
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node triggering action potentials at each node of Ranvier as it travels down the 
myelinated axon thus promoting consistent and rapid action potential propagation 
(Tasaki, 1939).   
 
Metabolic and trophic support of axons by OLs. Aside from the primary role for 
OLs in saltatory conduction, myelinating OLs also provide metabolic and trophic 
support to axons. Lee et al. (2012) recently demonstrated that the lactate 
shuttling monocarboxylate transporter 1 (MCT1) is highly enriched in OLs and 
disrupting oligodendroglial MCT1 results in both axon damage and neuronal loss 
in experimental models. Moreover, reduced MCT1 protein expression is a 
hallmark pathology observed in patients and in experimental models amyotrophic 
lateral sclerosis (ALS) which has provided a new glial based mechanism for ALS, 
a disease not classically thought of as involving OLs (Lee et al., 2012). 
 
Lastly, trophic support is provided to axons by myelinating OLs via secretion of 
insulin-like growth factor (IGF-1) and glial derived neurotrophic factor (GDNF). 
IGF-1 has been demonstrated to promote cortical neuron survival (Wilkins et al., 
2001). Both OPCs and OLs secrete factors which promote local axon viability via 
a PI3 kinase/Akt-signaling pathway. On the other hand, only mature OLs 
secreted factors which resulted in enhanced neurofilament phosphorylation-
driven neurite outgrowth via a MAP kinase/Erk-dependent signaling pathway. 
Oligodendroglial GDNF has been identified as a primary factor responsible for 
the MAPK/Erk-driven axonal outgrowth and together with IGF-1, provides an 
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Following multiple CNS diseases, ischemia and trauma, OL loss (demyelination) 
is typically observed to varying degrees within white matter. The degree of 
demyelination is dependent on the nature and severity of the disorder which will 
be more specifically addressed below. However, there is a biological sequelae 
associated with demyelination, and with the loss of protection and loss of trophic 
support to axons.  
 
Specifically, complete OL loss, perturbed OL maintenance and lack of myelin 
compaction each can result in dysfunctional axonal conduction. Therefore, 
conventional imaging techniques such as diffusor tensor imaging (DTI) or 
computed tomography (CT) scans, while adequate at identifying widespread OL 
loss in white matter, may not be sensitive enough to accurately identify subtle 
changes in myelin compaction and loss of trophic support. However, in each of 
these cases, axonal conduction properties will be compromised.  
 
Aside from the problems associated with altered or abolished electrical 
conduction, the lack of protection provided by OLs leaves axons susceptible to a 
host of potential secondary insults, including but not limited to: glutamate toxicity, 
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Ca2+ influx, systemic inflammatory cell infiltrate and reactive oxygen species 
(ROS) production. Each of the events mentioned are associated with the loss of 
axonal protection and have been implicated in axonal damage or neuronal death. 
Moreover, OL loss also results in a loss of trophic support normally provided by 
mature OLs to axons. As a result, focal CNS demyelination can have profound 
effects on the survivability of demyelinated axons not only within the 
demyelinating lesion (as identified via MRI imaging), but in more remote areas of 
white matter where myelin trophic support and myelin compaction are sub-
optimal following the secondary demyelination which is not identifiable. Without 
the OL-provided trophic support, axons will begin to degenerate in regions of 
severe OL loss, but this effect is not limited to only the demyelinated areas as the 
trophic factors secreted by OLs also contribute to axonal viability in white matter 
areas remote to the lesion. Taken together, this suggests that although 
demyelination is primarily due to a loss of myelinating OLs, there are also 
secondary components involving neurons and other glia as well. 
 
Clinical Significance of OL loss 
 
Significant functional loss is observed in multiple post-traumatic induced- and 
disease-induced forms of demyelination. Although the variety of sub-classes 
within each of these diseases is vast, they can be classified into 2 main groups: 
Genetic demyelinating disease and acquired demyelinating disease (Ben-Hur 
and Goldman, 2008). Each of these present a substantial reduced patient quality 
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of life coupled with a long-term financial burden. As each group of demyelinating 
disease is unique biologically, clinically and etiologically, they will be 
independently addressed in detail below. 
1. Genetic demyelinating diseases. The leukodystrophies comprise a 
collection of disorders resulting in the loss or dysfunction of not only OLs, 
but other glia and neurons in both children and adults (Kohlschütter and 
Eichler, 2011). Although the primary anatomical correlate of dysfunction 
associated with each of these is OL loss, the nature of this loss stems 
from heterogeneous causes which are addressed in more detail below. 
 
Pediatric Leukodystrophies (Alexander disease, Canavan disease and 
Krabbe disease) are a group of rare inherited disorders resulting in fatality 
during childhood. Limited treatment options are available but even in the 
best cases, mortality occurs prior to adolescence. Canavan disease is the 
most common pediatric leukodystrophy with an onset typically observed at 
birth with fatality occurring before 4 years of age (Matalon and Michals-
Matalon, 1999). However, in patients with milder forms of the disease, life 
expectancy can extend into the early twenties (Gordon, 2001). It is an 
autosomal recessive disease caused by a mutation in the aspartoacylase 
(ASPA) gene resulting in deficient enzymatic breakdown of N-acetyl 
aspartate. When not properly metabolized, NAA accumulates resulting in 
a chemical imbalance which interferes with myelin formation during 
development. Moreover, NAA accumulation is also toxic to existing myelin 
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(Matalon & Michals-Matalon, 1999). Assadi et al. (2010) recently 
demonstrated that treatment with lithium citrate slightly reduced intra-
cerebral NAA levels in a cohort of 6 infants < 10 months old. However, no 
treatment effect was reported for clinical outcome and myelin status.  
 
Alexander disease typically occurs from birth to 2 years of age (Alexander, 
1949; Messing et al., 2012). However, in very rare cases, a juvenile form 
(onset by 6 years of age) and an adult form (onset by 10 years of age) can 
be observed (Pareyson et al., 2012; Messing et al., 2012). It is an 
autosomal dominant disease caused by mutation in the GFAP gene and 
primarily affects white matter in the brain stem and cerebellum (Li et al., 
2002). Krabbe disease typically occurs from birth with patient’s life 
expectancy being less than 2 years of age due to its rapid progression 
(Kohlschütter and Eichler, 2011). However, rare cases of a late onset form 
have been documented and normally display a slower progression (Debs 
et al., 2013). It is an autosomal recessive disease resulting from mutations 
in the GalC gene located on chromosome 14 (Sakai, 2009). GalC is 
responsible for the breakdown of sphingolipids, a major component of 
myelin following GalC metabolic dysfunction, resulting in lipid 
accumulation which interferes with proper myelin formation and 




Vanishing white matter (VWM) disease is unique among the 
leukodystrophies as it seems to only affect OLs and astrocytes with little to 
no pathology seen in other CNS glia, vasculature or axons (van der Knaap 
et al., 2006). Onset is thought to occur at birth with patients first being 
symptomatic between 2-6 years of age (van der Knaap et al., 2006). 
However, late onset has been documented late into adulthood and is 
commonly misdiagnosed as schizophrenia due to white matter loss-
induced psychosis (Matsukawa et al., 2011; La Piana et al., 2012). 
Although it has been characterized as an autosomal recessive disease 
caused by a mutation in any one of the 5 genes which encode various 
subunits of the translation initiation factor EIF-2B (EIF2B1, EIF2B2, 
EIF2B3, EIF2B4, and EIF2B5; Pronk et al., 2006), the exact mechanism of 
OL death remains elusive. One theory of mechanism is that OLs and 
astrocytes both synthesize large amounts of proteins putting OLs under 
high metabolic demand. Therefore, when production of translation 
initiation factors are perturbed, the metabolic demand becomes too 
exhaustive for the OL to maintain and overall protein synthesis becomes 
dysfunctional or completely compromised depending on which specific 
subunits are affected by the mutation. OL death imminently proceeds as 
apoptotic cascades are initiated following the loss of metabolic sustenance 
(Pronk et al., 2006). Following clinical diagnosis, a myriad of progressive 




Lysosomal storage disorders are diseases characterized by dysfunctional 
lipid metabolism. Metachromatic leukodystrophy (MLD) is a common form 
of lysosomal storage disease and presents in 3 forms: late infantile, 
juvenile and adult. Late infantile MLD is the most common and children 
usually die before the age of 5 (Fluharty, 2006). It is an autosomal 
recessive disease classified by an arylsulfatase A deficiency resulting in 
sulfatide accumulation-induced toxicity which is well accepted as being 
responsible for the loss of myelin (Poeppel et al., 2005). However, 
sulfatide accumulation has been suggested by others to be non-toxic 
bringing into question classical dogma (Blomqvist et al., 2011). These 
authors have proposed a model where sulfatide accumulation is not the 
sole source of demyelination as lysosphingolipid accumulation (a 
metabolite of sulfatide) may also play a role as it is cytotoxic to OLs in vitro 
(Blomqvist et al., 2011). The late infantile form typically presents clinically 
around 4-8 months as severe motor and developmental dysfunction with 
few children surviving past the age of 5 (Kohlschutter and Eichler, 2011). 
The juvenile form can present as early as age 3 but more commonly is 
recognized when the patient begins to display progressive cognitive 
dysfunction in school eventually resembling infantile MLD. These patients 
normally die within 10-15 year of diagnosis (Krageloh-Mann et al., 2013). 
The adult form begins in late adolescence initially presenting as a 
psychiatric disease which slowly progresses to dementia and ultimately 
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death. However, adult onset MLD is the slowest progressing form of MLD 
with patients having reported living for decades (Sadovnick et al., 1993).         
 
2. Acquired demyelinating diseases. Acquired demyelinating diseases 
comprise a collection of disorders primarily affecting adults but in rare 
occasions may affect the pediatric population as well.  
 
Multiple sclerosis (MS), the leading cause of neurological disease in 
young adults, is the most common of disease in this group (Evans et al., 
2013). It was initially suggested to be an autoimmune disease as there are 
similarities between T-cell immunoreactivity in human MS and 
experimental allergic encephalomyelitis, a rodent model of MS 
(Constantinescu et al., 2011). However, others have countered that 
demyelination is not induced following transfer of serum or T-cells from an 
MS patient (Jones et al., 1995). Its hallmark pathology is the presentation 
of MS plaques throughout the white matter and can be identified with 
conventional magnetic resonance imaging (Ge, 2006). Although MS 
etiology has been suggested to involve both environmental factors and 
genetic susceptibilities, identification of the specific biological events that 
result in acute inflammatory injury to axons and glial cells remains elusive. 
MS can further be categorized into 4 sub-groups: Classic MS, acute MS, 
neuromyelitis optica and concentric sclerosis. Although each sub-group 
displays the hallmark characteristics of MS, a brief description of their 
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distinctions in provided below. Acute MS is difficult to categorize as it has 
been suggested to be very aggressive forms of acute‐disseminated 
encephalomyelitis (ADEM), an inflammatory disease primarily affecting 
children (Bester et al., 2014). In any case, its clinical presentation is rare. 
Neuromyelitis optica is distinct from classical MS in that during the acute 
phase, clinical presentation starts with vision loss (due to optic nerve 
demyelination) and soon progresses to paraplegia and sensory loss (due 
to spinal cord demyelination). Patients who survive the acute phase 
normally have chronic functional deficits resulting from demyelination and 
axonal loss within the spinal cord. Lastly, concentric sclerosis is perhaps 
the most unmistakable form of multiple sclerosis with a clinical 
presentation characterized by bands of white matter lesions which 
alternate with bands of normal appearing white matter. It typically 
progresses rapidly and may also occur concomitantly with more classical 
MS plaques (Sato et al., 2012).  
 
Ischemic-induced demyelination is most commonly observed in 
cerebrovascular disease, with the primary pathology located in sub-
cortical white matter. These patients will develop dementia and 
neurological deficits with the most identifiable characteristic being marked 
arteriosclerosis and arteriolosclerosis within the deep cerebral white 




Traumatic brain injury (TBI) and spinal cord injury (SCI) comprise the most 
complex diseases which include a demyelinating component. Although 
both TBI and SCI are implicated as primary and secondary inducers of 
demyelination, more attention has focused on SCI in the context of 
demyelination because it has a much higher proportion of myelin relative 
to the brain. Injury spinal white matter and the subsequent demyelination 
is well described (Norenberg et al., 2011). Not only is there a component 
of vascular disruption similar to what is observed following stroke, but SCI 
can involve direct damage to all cell types local to the lesion as well as 
chronic secondary effects in spinal segments distant to the lesion 
epicenter. In animal models, chronic demyelination has been described 
(Gledhill et al., 1973; Blakemore, 1974; Gledhill and McDonald, 1977; 
Blight, 1983; Totoiu and Keirstead, 2005) while little chronic demyelination 
is reported in humans (Gensert and Goldman, 1997; Kakulas, 1999; Guest 
et al., 2005). However, recent evidence has suggested that remyelination 
is far more extensive in animal models when accounting for which axons 
remain spared and traverse the lesion (Lasiene et al., 2008). 
Remyelination occurred successfully when axon viability was maintained 
making the extent of remyelination directly proportional to the number of 
spared axons. This agrees with clinical data suggesting that successful 
spontaneous remyelination can also occur in human SCI but following 
chronic demyelination, axons begin to degenerate and neurons die limiting 
the capacity for remyelination. Considering that remyelination is slow, it is 
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imminent that even in the best case scenarios, at least some axons will be 
lost. Moreover, experimental advances made in the field of axonal 
regeneration have now demonstrated that spinal cord axons can regrow 
over long distances (Houle and Cote, 2013) but these newly formed axons 
would not have myelin making their functional capacity questionable. 
Therefore, any therapeutic strategy attempting to promote the regrowth of 
axons across a lesion would certainly require supplementation of available 
OP pools with transplanted OPs in order to provide the glial support 
required for optimal axonal conduction.  Taken together, these 
considerations suggest that increasing the overall numbers of endogenous 
OPs or supplementing OP populations with transplantation approaches 
both have the potential to enhance remyelination and reduce axon loss if 
applied before demyelination reaches a chronic stage or following axonal 
regrowth.   
 
Other etiologies included in acquired demyelinating disease are chemical- 
and viral induced demyelination, which are both rare with few common 
mechanism of induction making them more difficult to define as a thematic 
group and they will not be addressed here.  








Remyelination was first described in the PNS following crush-induced 
demyelination of the sural nerve in rabbits (Quilliam, 1958). It was first described 
in the CNS following demyelination of feline spinal cord by repeatedly withdrawal 
and re-injection of cerebrospinal fluid (CSF; Bunge et al., 1961) and since has 
also been extensively described in rodents (Blakemore and Franklin, 2008), 
primates (Radtke et al., 2004) and humans (Kipp et al., 2012). In rats, toxic 
demyelination models using ethidium bromide (EB; Blakemore and Franklin; 
2008) and lysolecithin (Gregson and Hall, 1973) as well as trauma-induced 
demyelination (SCI; Totoiu and Keirstead, 2005) have provided a platform to 
assess remyelination which takes advantage of the advanced behavioral 
assessment methods available for rat studies (Onifer et al., 2007). In mice, 
cuprizone ingestion (Torkildsen et al., 2008), experimental autoimmune 
encephalopathy (EAE; Constantinescu et al., 2011) and mutant strains of mice 
lacking in genes necessary for myelin formation (Windrem et al., 2008; Wang et 
al., 2013) have all been used as a platform to assess remyelination. Of all rodent 
demyelination models, low concentration EB (Franklin and ffrench-Constant, 
2008) and lysolecithin (Jeffery and Blakemore, 1995) injection as well as the 
cessation of cuprizone demyelination (Matsushima and Morell, 2001) each 
exhibit a spontaneous remyelination response which is driven by OPs. Work 
done employing these models has been used to generate data which has 
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provided much of our knowledge about the signaling pathways and mechanisms 
involved during remyelination.                  
 
Oligodendrocyte progenitors (OPs). It has been well described that OPs persist 
in adult rodent white matter in a mitotically competent state and are the primary 
substrate by which endogenous remyelination occurs (Blakemore et al., 1995; 
Gensert and Goldman, 1997). OPs have also been isolated from adult human 
white matter using FACS based identification of reporter expression driven off of 
OP-specific promoters (Roy et al., 1999). When cultured, the human OPs (hOPs) 
proliferated and differentiated into mature mixed glial populations with a 
predominantly oligodendroglial phenotype. It has been suggested that successful 
endogenous remyelination in the CNS is often perturbed due to axon loss, 
inflammation, myelin debris, the glial scar and lack of the appropriate cues 
required to direct remyelination (Back et al., 2005; Kotter et al., 2006; Fuller et 
al., 2007; Giger et al., 2008; Fancy et al., 2009). However, this has been 
challenged as being an animal model-specific phenomenon as spontaneous 
remyelination has been described in human MS patients (Kipp et al., 2012). This 
discrepancy has been suggested to result from a failure to assess remyelination 
of intact axons as accounting for this discrepancy showed near normal 
myelination patterns in spared rodent axons following spinal contusion (Lasiene 




OP engraftment. In an effort to enhance endogenous remyelination, OP cell 
transplantation studies in animals have begun to identify the necessary 
considerations for implementation in the clinical setting. Many groups have 
demonstrated that following transplantation of OPs isolated in vivo, there is 
evidence of graft survival and successful integration within the host CNS. 
However, obtaining OPs with approaches that isolate them from whole tissue 
does not yield the number of OPs necessary for clinical consideration (Ben-Hur 
and Goldman, 2008). Therefore, several groups have begun to use embryonic 
stem (ES) cells as a source for OPs as they can be limitlessly expanded ex vivo 
prior to their differentiation into OPs (Ben-Hur and Goldman, 2008). Brustle et al. 
(1999) was the first to report remyelination following ES cell-derived OP 
engraftment. Using a rat model of Pelizaeus-Merzbacher disease (PMD) where 
(similar to human patients) PMD rats carry a mutation in the X-linked PLP gene 
resulting in myelin deficiency (Hodes et al., 1993), isolated ES cells were 
differentiated in vitro into OPs, expanded to scale for transplantation and injected 
into the spinal cord of PMD rat pups (Brustle et al., 1999). Two weeks post-
injection, ultrastructural analysis of demyelinated white matter within the dorsal 
column of OP-injected PMD rats exhibited abundant myelin sheaths as 
compared to control PMD rats. Han et al. (2004) isolated A2B5+ glial restricted 
precursor (GRP) cells from E13.5 rat embryos transgenically expressing alkaline 
phosphatase using flow activated cell sorting (FACS). Sorted GRPs were then 
expanded and engrafted into the cervical spinal cord following unilateral 
hemisection of the lateral funiculus. Tracking the GRP grafts with human alkaline 
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phosphatase expression revealed that they migrated throughout the lesion and 
matured in a context specific manner (i.e. astrocytic phenotype in grey matter 
and oligodendroglial phenotype in white matter) but axonal remyelination, 
functional recovery and the efficiency of OL genesis was not reported. This may 
be due to the author’s choice of lateral funiculus laceration as an injury model 
which would presumably spare few axons leaving behind a poor substrate for 
remyelination. However, when engrafted into the adult dysmyelinating shiverer 
mouse, a model with spared axons but lacking compact myelin, transplanted 
human ES cell-derived OPs were able to integrate, differentiate and form 
compact myelin (Nistor et al., 2005). Of all transplantation studies mentioned, 
most do not report behavioral function or electrophysiological responses, 
diagnostics necessary to assessing the integrity of functional myelin. This may be 
because the model used to assess demyelination did not provide clear-cut 
outcome measures sufficient for a functional deficit to be accurately assessed. 
Therefore, because of the variety of behavioral and electrophysiological tools 
available for functional assessment following SCI, the spinal cord has provided a 
useful substrate to assess functional remyelination. Specifically, the Basso, 
Beattie and Bresnahan (BBB) scale for open-field locomotor function (Basso et 
al., 1995) and trans-cranial magnetic motor-evoked (tcMMEP) response 
conduction for electrophysiological function (Magnuson et al., 1999) are the most 
common techniques used to evaluate behavioral function and 
electrophysiological response conduction, respectively. Therefore, several 
studies have investigated the therapeutic potential of OP engraftment using SCI 
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as a model for demyelination (Bambadakis and Miller, 2004; Cao et al., 2005; 
Karimi-Abdolrezaee et al., 2006; Cao et al., 2010; Hofstetter et al., 2005). In all 
but one publication (Kierstead et al., 2005), the transplanted OPs had been 
engineered to express growth factors. However, not only were the growth factors 
manipulated different, but the source of OP was different in each experiment: 
Bambadakis and Miller, 2004 – OPs immunopanned from rat pup cortex / Shh; 
Cao et al., 2005 – glial restricted precursors (GRPs) / Brain derived neurotrophic 
factor (BDNF)/Neurotrophin-3 (NT3); Karimi-Abdolrezaee et al., 2006 – Neural 
precursor cells (NPCs) / Platelette derived growth factor (PDGF), fibroblast 
growth factor 2 (FGF2) and endothelial growth factor (EGF); Cao et al., 2010 – 
OPs ilsolated from adult rat spinal cord / ciliary neurotrophic factor (CNTF); 
Hofstetter et al., 2005 – NPCs / Neurogenin-2). Unfortunately, there is a 
significant lack of standardization across laboratories with respect to therapeutic 
manipulation, choice of modelling and choice of cell source. This is certainly an 
issue which must be reconciled in order to effectively and reliably replicate 
experimental data with the hope to ultimately translate these therapies to the 
clinic.   
 
The utility of using rodent models to address questions specific to human 
oligodendrocyte biology has been useful. However, the experimental advantage 
of using human- rather than animal-derived OPs could obviate any concerns of 
species related differences between experimental animals and human patients 
as a limitation to translating research from bench to bedside. To that end, 
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chimeric mouse models were developed as a tool to assess hOP-driven 
remyelination in vivo thus providing insight into the source-dependent phenotypic 
differences in hOPs isolated from adult or fetal tissue as well as the feasibility of 
hOP engraftment as a clinically relevant treatment (Windrem et al., 2004).  
 
Human OPs can be isolated from both tissue derived sources (adult subcortical 
white matter or fetal forebrain) via FACS-based cell surface antigen detection or 
promoter-based reporter expression (Roy et al., 1999; Windrem et al., 2004) as 
well as derived from stem cell-like progenitor sources (embryonic or induced 
pluripotent stem cells hitherto referred to as hES cells and hiPSCs, respectively 
(Roy et al., 1999; Windrem et al., 2004). The engrafted fetal-derived hOPs 
displayed robust migratory behavior and differentiated in a context specific 
manner (i.e. OL differentiation in white matter and astrocyte differentiation in gray 
matter). However, their purity was marginal and the rate at which the 
remyelination occurred was slow. On the other hand, engrafted adult-derived 
hOPs were highly oligodendrocytic and remyelinated at a much faster pace than 
their fetal-derived counterparts but they displayed limited migratory distances and 
lacked the context specificity observed in transplanted fetal-derived hOPs when 
fully incorporated into the mouse CNS. Each hOP source has its advantages 
which may be exploited to adapt as treatments for different demyelinating 
diseases. For example, the widespread migratory patterns and context specific 
differentiation of fetal-derived hOPs may be more effective at treating the 
congenital leukodystrophies or the enzymatic pediatric leukodystrophies whereas 
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the high purity and rapid rate of remyelination in adult-derived hOPs may be 
more suitable for treating ischemic demyelination (as in stroke) or post-
inflammatory demyelination (as in multiple sclerosis). However, in both cases, 
challenges persist as allograft rejection is an ongoing concern. Moreover, limited 
tissue-derived hOP yield suggests that the idea of relying on isolated hOPs as a 
graft source scalable for clinical use may be unrealistic. Several groups have 
investigated the possibility of using human embryonic stem (hES) cells as a 
renewable source of hOPs but this too presents its obstacles (Nistor et al., 2005; 
Kang et al., 2007). Limited understanding of hES cell differentiation protocols and 
a lack of technology to absolutely exclude all potentially tumorigenic hES and 
hES-like cells from mixed cultures combined with allograft rejection concerns 
excludes hES cell-sources as a viable means to generate hOPs in high yield and 
purity. Moreover, although many genetic similarities are shared between hES 
cell-derived and fetal tissue derived neural progenitors, there are disparate 
differences observed when attempting to differentiate these progenitors into 
dopaminergic neurons as hES cell-derived progenitors could be driven to this 
phenotype while fetal-derived could not (Shin et al., 2007). It is likely that similar 
differences will be observed between differentiating hES cell-derived and fetal 
tissue-derived hOPs.  
 
Focus has recently shifted away from acquiring hOPs from hES cell sources with 
a particular interest in acquiring hOPs from human induced pluripotent stem cell 
(hiPSC) sources, primarily in an attempt to obviate immunorejection concerns. 
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hiPSCs engineered from adult fibroblasts can be indefinitely expanded in culture 
and differentiated into a myriad of CNS cell types both in vitro and in vivo 
(Yamanaka and Takahashi, 2006; Almeida et al., 2012; Emdad et al., 2012; 
Wang et al., 2013). Specifically, hiPSC-derived hOPs (hiPSC-OPs) have been 
recently shown to rescue the congenital hypomyelinating mouse (shiverer) using 
similar techniques to work previously mentioned with isolated fetal- and adult-
derived hOPs (Wang et al., 2013). The hiPSC-OPs displayed migratory activity 
and efficiency phenotypic of fetal-derived hOPs following neonatal chimerization 
of the shiverer mouse CNS. Moreover, long term monitoring following hiPSC-OP 
engraftment revealed no evidence of teratoma formation in all transplanted mice 
suggesting that hiPSC-OPs are non-tumorigenic in vivo (Wang et al., 2013). 
Taken together, these data suggest that as hiPSC-OPs are fit for scalable 
expansion, have a reduced concern for rejection and display no tumorigenicity, 
they carry the most potential for clinical translation when compared to hES cell-
derived or tissue-derived hOP sources.  
 
A caveat to the OP transplantation studies performed in the shiverer mouse is 
that although the shiverer mouse provides a useful model of genetic pediatric 
demyelination as affected mice typically die by one month (Chernoff, 1981), it is 
far more permissible to remyelination that the complex and hostile 
microenvironment observed following SCI or repeated episodes of inflammatory 
demyelination. Thus, while the shiverer mouse may provide a tool to assess OP 
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graft myelination potential, its utility as a model to assess OP engraftment from a 
translational perspective may be limited.  
 
MicroRNA (miRNA) Synthesis and Biological Function 
 
MicroRNAs (miRNAs) are a family of evolutionarily conserved 22-24 nucleotide 
noncoding RNAs regulating protein translation via posttranscriptional gene 
repression (Ambrose, 2004) thus acting as fine-tuners of eukaryotic gene 
expression. Recent literature supporting this hypothesis demonstrated a modest 
rather than an absolute suppression of protein output by miRNAs (Baek et al., 
2008; Selback et al., 2008). However, this does not obviate the need for research 
involving miRNAs as therapeutic targets as there several examples where a 
small fold change in miRNA expression levels results in dramatic alterations of 
cellular processes; this may be due to miRNAs ability to repress many targets 
with similar functions (Flynt and Lai, 2008). miRNA genes are primarily encoded 
within the introns of protein-coding genes, and to a lesser extent in 
monocystronic units and polycystronic clusters (Bartel, 2004). RNA polymerase II 
is responsible for the transcription of miRNA genes into stem-loop transcripts 
termed primary miRNAs (pri-miRNAs).  Following cleavage by the RNase III 
nuclease Drosha, pri-miRNAs yield a ~65 nt precursor miRNA (pre-miRNA) 
which is exported out of the nucleus by Exportin 5.  Once in the cytoplasm, pre-
miRNAs are processed by Dicer, a second RNase III enzyme yielding 19-25 
double stranded duplexes which are subsequently unwound into sense and 
28 
 
antisense strands by a helicase.  The mature miRNA strand can then associate 
with Argonaut proteins and other factors to form the miRNA-induced silencing 
complex (miRISC; Fig. 1A,B). Argonaute proteins provide the catalytic activity of 
the miRISC while the miRNA drives the targeting of the miRISC (Cenik & 
Zamore, 2011). The ability of miRNAs to target certain mRNAs primarily relies on 
a miRNA “seed” region (nucleotides 2-9 at the 5’ end of the miRNA). When 
targeting exhibits a true complementarity (Carthew and Sontheimer, 2009), 
mRNA degradation is favored. When targeting is imperfectly complimentary, 
translational repression is favored (Hu and Coller, 2012). Association of the 
miRISC with a target transcript finally results in a reduction in protein levels for 
target transcripts whether it occurs via translational repression or mRNA 
degradation (Baek et al., 2008; Selback et al., 2008).   
 
It is the nature of this imperfect complimentary binding that lends to the potential 
of using and/or targeting miRNAs as therapeutic targets for disease. Considering 
that miRNA binding is primarily directed by base pairing of the 7-8 nucleotide 
seed sequence to target mRNA rather than base pairing of the entire 22-23 
nucleotide sequence to target mRNAs in perfect complementarity, the wide range 
of mRNA targets which can be regulated by one miRNA can be in the hundreds 
to the tens of thousands (Ghelani et al., 2012; John et al., 2004). Therefore, 
therapeutic manipulation of a single miRNA has the potential to manifest as 




miRNAs and oligodendroglia  
 
The role of miRNAs in post-transcriptional and translational regulation has been 
widely described in oligodendroglia in vitro (Lau et al., 2008; Dugas et al., 2010) 
and in vivo (Zhao et al., 2010). Moreover, Lau et al. (2008) described that not 
only are there distinct cell type-specific miRNA expression profiles 
(oligodendroglia versus other CNS cellular lineages),  there are also distinct 
stage-specific expression profiles within the same cellular lineage (A2B5+ 
expressing versus GalC+ expressing oligodendroglia isolated from the developing 
rat brain).  
 
Multiple in vivo studies have identified miRNAs miR-34a, -155 and -326 as being 
dysregulated in active versus inactive MS lesions (Junker et al., 2009). Yet, the 
majority of miRNAs exhibiting the most robust changes are due to other non-
oligodendroglial cell types (mainly reactive astrocytes and inflammatory cells; 
Junker et al., 2009). Following spinal cord injury (SCI), a disease typically 
associated with OL loss and limited OPC remyelination, miRNA dysregulation is 
observed within the epicenter of the injured rat spinal cord relative to sham 
controls (Liu et al., 2009). However, these studies performed the miRNA analysis 
on whole tissue samples and lack cell specificity. Zhao et al. (2010) 
demonstrated the importance of oligodendroglial-specific miRNAs during 
zebrafish development by dicer ablation which abolishes all miRNA processing 
and maturation but this does not establish which individual miRNAs are involved 
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and what their expression profile is. Few studies have reconciled the need for cell 
specificity by assessing oligodendroglial miRNAs in monoculture. Specifically, 
two papers simultaneously released in 2010 each identified miR-338 and miR-
219 as being crucial to oligodendroglial function in several in vitro models (Dugas 
et al., 2010; Zhao et al., 2010). Taken together, these data suggest that although 
it is likely that there are miRNA expression profiles common to many if not all 
myelinating processes, it is reasonable to assume that there are also distinct 
miRNAs involved which specifically regulate various OP-behaviors, including but 
not limited to: proliferation, migration, fate-commitment, context specificity, 
differentiation and remyelination. 
 
Summary of experimental directions 
 
Genetic mouse models are powerful tools to address specific mechanistic 
questions about disease pathology and treatment when coupled with other 
models of demyelination as SCI, TBI and EAE. The rat model of ethidium 
bromide (EB) demyelination has been used extensively to investigate the loss of 
myelin and glia, the post-demyelination inflammatory response and remyelination 
(Blakemore and Franklin, 2008). However, rats carry little to no potential for 
genetic manipulation. Therefore, we attempted to develop a model of EB 
demyelination in the mouse. Chapter 2 addresses the similarities and differences 
between the rat and mouse following EB injection into the thoracic spinal cord. 
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Additionally, the importance and distribution of locomotor pathways within 
mammalian spinal white matter is reinforced.  
 
Past studies have demonstrated the ability to accurately assess rodent ventral 
locomotor pathways using in vivo electrophysiology. Targeting stimulation to sub-
cortical areas or the brainstem, a transcranial magnetic motor-evoked potential 
(tcMMEP) response can be elicited and recorded from the hindlimbs. However, 
studies initially characterizing tcMMEP responses in mice were elicited with a 
custom prepared magnetic stimulator not commercially available (Hill et al., 
2009). Therefore, Chapter 3 addresses the fact that unlike in the rat, mouse 
tcMMEP response assessment in mice is unreliable using the current 
commercially available technology. 
 
Following demyelination, there is a population of mitotically competent OPs 
which are harbored in the CNS throughout adulthood and are well known to 
possess the potential to successfully remyelinate during myelin maintenance 
(Iester et al., 1997) and in select animal models (Blakemore and Franklin, 2008). 
Therefore, the development of therapeutic targets within OPs which may facilitate 
remyelination in diseases where the process is inhibited or abolished is of high 
clinical priority. Chapter 4 addresses the role of microRNAs (miRNAs) in 
remyelinating OPs and identifies potential therapeutic miRNA targets by which 
remyelination can be improved. Lastly, in Chapter 5 we will address the overall 
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conclusion of all data presented as well as the clinical implications and 
































Figure 1. miRNA-induced translational repression of target mRNA. Schematic 
demonstrating that in the absence of miRNA expression, target transcripts are 
translated to protein (A). Following induction, miRNAs assembly into the miRISC 
thereby directing translational repression via base pairing to complementary 






























FUNCTIONAL CONSEQUENCES OF ETHIDIUM BROMIDE DEMYELINATION 




Ethidium bromide (EB) has been used extensively in the rat as a demyelinating 
model to assess endogenous remyelination (Blakemore & Franklin, 2008), 
remyelination by engrafted cells (Tetzlaff et al., 2011; Enzmann et al., 2006) and 
to identify white matter tracts responsible for locomotion (Loy et al., 2002a,b).  
Both OL and astrocyte loss are hallmarks within the epicenter of an EB lesion 
while axons remain unaffected (Blakemore, 2005). The mechanism of selective 
glial death has been suggested to occur through EBs action as a minor-groove 
DNA intercalator (Blakemore, 1982; 1984). However, other evidence suggests 
that while EB does intercalate both chromosomal and mitochondrial DNA 
(mtDNA), it only affects transcription of mtDNA (Hayakawa et al., 1979; 
Desjardins et al., 1985; Hayashi et al., 1990). Therefore, it is likely that EB 
injection into white matter compromises mtDNA transcription in all cells local to 
the lesion with neurons and endothelial cells being preferentially less sensitive 




Past literature has reported the acute use of EB into the dorsal columns of the 
adult mouse, but the EB concentrations were low and no chronic time-points 
were used to assess remyelination status (Fushimi & Shirabe, 2002; 2004). 
Considering the potential of genetic mouse models in assessing mechanism(s) of 
remyelination, we set out to characterize the cellular and behavioral responses to 
EB injection into the adult mouse spinal cord. To understand how ventral motor 
pathways modulate/control hindlimb locomotion in the mouse, demyelination was 
targeted to the ventrolateral funiculus (VLF) and ventral column (VC), together 
referred to as ventral white matter (VWM). In the rat, multiple ventral and dorsal 
pathways contain descending information involved in locomotion and functional 
deficits are only observed when more than one pathway is lost (Jordan, 1986; 
Jordan, 1991; Loy et al., 2002a,b; Schucht et al., 2002; Noga et al., 1991; 
Steeves and Jordan, 1980). Here, we additionally asked whether the 
organization of ventral motor pathways in the mouse is similar to the rat.  
 
Materials and Methods  
 
Animals. All animal procedures were performed in strict accordance with the 
Public Health Service Policy on Humane Care and Use of Laboratory Animals, 
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 
Resources, National Research Council, 1996), and with the approval of the 
University of Louisville Institutional Animal Care and Use Committee. A total of 
116 female C57Bl/6 mice 6-8 weeks of age were used for all experiments 
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(Charles River; Wilmington, MA). For the initial injection parameter pilot 
experiment, each group contained 4 mice (0.15 mg/mL EB, 0.20 mg/mL EB, 0.25 
mg/mL EB and saline).  To characterize the effect of 0.20 mg/mL EB or saline, a 
total of 48 mice were used and allowed to recover for 2 weeks (n=11 EB, n=9 
saline) or 8 weeks post-injection (n=16 EB, n=12 saline). A total of 10 mice were 
used for EM imaging (n=2/group; saline or 1, 2, 3, 4 or 6 weeks post 0.20 mg/mL 
EB).  
 
Surgery. Mice were anaesthetized with 2.0% avertin (2,2,2-tribromoethenol in 
1.25% 2-methyl-2-butanol in saline), treated with 1 cc sterile saline (s.c.) and 
lacrilube for the eyes. All surgery and post-op procedures were performed on a 
37C heating pad. Injections were performed using a 45° beveled glass 
micropipette (internal diameter ~25 µm) driven by a Parker II picospritzer (Pine 
Brook, NJ). After a laminectomy and durectomy at the T10 vertebral level, mice 
were placed in a stereotaxic device and two 0.25 µl boluses of either EB (at 
concentrations of 0.15 mg/mL, 0.20 mg/mL, 0.25 mg/mL EB in saline) or saline 
spaced 1 minute apart were injected into 2 locations separated by 1.5 mm rostro-
caudally within the laminectomy. Injections were bilateral, approached at an 18° 
angle to a depth of 1.1 mm and centered 0.45 mm lateral from midline. Following 
injections, the needle was left in place for 3 minutes to allow the EB or saline to 
diffuse. Following post-op suturing and care, mice were treated prophylactically 
with gentamycin and a second 1 cc bolus of sterile saline (s.c.) and placed in 
heated recovery cages with alpha-dry bedding. Buprenorphine (0.05 mg/kg) was 
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administered twice daily for 48 hours and bladders were expressed as needed 
(up to 2-3 times/day). All mice experienced identical housing and recovery 
conditions prior to and 1 week following EB.  
 
Characterization of Behavioral and Cellular Responses to EB. Previous studies 
showed the medial VLF carries signals important for locomotion in the rat spinal 
cord (Loy et al., 2002a,b; Cao et al., 2009). Pilot studies revealed a steep does-
response curve for axon sensitivity to EB in mouse VWM as 0.25 mg/mL EB 
completely destroy axons 2 weeks post-injection whereas spinal cords injected 
with 0.15 mg/mL display little to no demyelination (data not shown). 0.20 mg/mL 
EB consistently destroyed glia within the lesion epicenter while leaving axons 
apparently intact at 2 weeks (Fig. 2C). To confirm accuracy of the injections, 
serial cross sections throughout the lesion were stained with eriochrome cyanine 
(EC) to visualize myelinated and demyelinated areas (Fig. 2B).  
 
Basso Mouse Scale (BMS). The BMS (Basso et al., 2006; Engesser-Cesar et al., 
2005) was used to assess hindlimb function at baseline, and weekly for 5 weeks 
following EB injection. Mice were scored by two raters (trained by Dr. Basso and 
colleagues at the Ohio State University) blinded to the experimental condition.  
 
Treadscan®. We utilized the Treadscan® system (Clever System Inc., Reston, 
VA) to assess gait, coordination and paw rotation during forced locomotion 
(Beare et al., 2009; Saraswat Ohri et al., 2011). Treadscan® related measures 
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analyzed were: run speed, hindlimb rotation, regularity index (RI), total coupling 
and body rotation. Run speed was the maximum speed mice were able to 
maintain optimally coordinated locomotion. Hindlimb rotation and body rotation 
were calculated as absolute degrees from midline. Total coupling was calculated 
as follows: the percent deviation (absolute value) from naïve mice from 
homolateral, homologous and diagonal coupling measures summed together. 
Hindlimb rotation, body rotation and RI values were obtained manually. 
Treadscan® analysis was performed terminally, immediately prior to tissue 
processing.  
 
Tissue Processing. Mice were sacrificed with an overdose of avertin (2.0%) and 
transcardially perfused first with cold phosphate buffered saline (PBS) until the 
liver was clear and subsequently with cold 4% paraformaldehyde (PFA) in PBS. 
Spinal cords were dissected and allowed to post-fix for 24 hours in 4% PFA in 
PBS, then cryoprotected in 30% sucrose in PBS for 72 hours, both at 4C. Spinal 
cords were blocked in tissue freezing medium (Triangle Biomedical Sciences, 
Durham, NC) and frozen at -20°C prior to sectioning with a Leica cryostat 
(Buffalo Grove, IL) at 20 m. Sections were transferred to coated slides and 
stored at -20°C.     
 
EC Staining. Tissue sections were stained with EC to distinguish myelinated from 
unmyelinated spinal cord axons. The percentage of spared white matter (SWM) 
surface area from an entire cross-section at the level of injection from EB injected 
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mice relative to saline injected control mice was calculated as described 
previously (Magnuson et al., 2005; Cao et al., 2010; Saraswat Ohri et al., 2011). 
Brightfield images were captured with a Nikon Eclipse TE 300 inverted 
microscope and a spot CCD camera. White matter was traced with Nikon 
Elements software and epicenters were defined as the segment(s) with the least 
SWM. Percent SWM was calculated by comparing these numbers to identically 
processed control spinal cord at the identical spinal level. For ventral SWM 
analysis, regions of interest (ROIs) were defined as the ventral half of the cord 
with the equatorial line centered on the central canal (Fig. 3B).   
 
Immunohistochemistry (IHC). To characterize the cellular effect of EB or saline 
injections following 2 or 8 weeks of recovery, animals were sacrificed, perfused, 
fixed and spinal cord tissue processed as described above. To determine the 
extent of inflammation within the lesion epicenter, IHC against the common 
leukocyte antigen CD45 was used at 2 weeks (n=11 EB, n=9 saline) and 8 
weeks (n=9 EB, n=8 saline). Hoechst™ was used to identify nuclei. To determine 
the epicenter ROI on IHC sections, an adjacent EC stained section (<100 µM 
away) was superimposed over the IHC section in Photoshop™ and made 
partially transparent so the EC epicenter ROI could be traced over the 
appropriate area. To determine the effect of 0.20 mg/mL EB on axonal patency, 
sections were stained with primary antibodies against NF-M to assess axon 
number and diameter within the epicenter.  Staining protocols were as follows: 
tissue sections were blocked with 5% bovine serum albumin (BSA), 10% normal 
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donkey serum (NDS), and 0.1% Triton-X-100 in tris-buffered saline (TBS) for 1 h 
at room temperature. Primary polyclonal antibodies neurofillament M (NF-M) 
(rabbit, 1:250, Millipore; Billerica, MA), glial fibrillary acidic protein (GFAP; rabbit, 
1:500, Dako; Carpinteria, CA), CD45 (rat, 1:500, Millipore) and myelin basic 
protein (MBP; rat, 1:250, Millipore) were incubated for 24 hrs at 4°C with 5% 
BSA, 5% NDS, and 0.1% Triton-X-100 in TBS. Sections were then washed at 
room temperature (x 3) with TBS and incubated with fluorescein (FITC; 1:200) 
and rhodamine (TRITC; 1:200)-conjugated F(ab’)2 secondary antibodies 
(donkey, Jackson ImmunoResearch; West Grove, PA) for 1 h at room 
temperature. Species-specific IgG isotype controls were used to account for any 
non-specific binding or other cellular protein interactions. IHC imaging was done 
on a Nikon Eclipse TE 300 inverted microscope with a spot CCD camera. 
Exposure times remained identical across all images. To define the EB lesion 
epicenter ROI on IHC sections, an adjacent EC stained section (<100 µM away) 
was superimposed over the IHC section in PhotoshopTM and made partially 
transparent so that both the EC and IHC images could be visualized 
simultaneously to accurately line up the sections. Using the EC section as a 
guide, epicenter ROIs were traced and ROIs saved. Finally, the traced ROI file 
was opened along with its respective IHC image to allow for area and intensity 
analysis. A subset of mice at the 8 week time-point were sacrificed and total RNA 




Electron Microscopy (EM). Tissue was fixed in buffered 2% glutaraldehyde 
followed by 1% buffered osmium oxide, dehydrated in ethanol and embedded in 
LX 112 (Ladd Research Industries, Williston, VT). Appropriate areas were 
selected for examination and thin sectioned for EM. Thin sections were stained 
with uranyl acetate and lead citrate for viewing under a Philips CM-12 
transmission electron.    
 
Quantitative real time polymerase chain reaction (qRT-PCR). Total RNA was 
extracted from whole spinal cord epicenters of EB mice (n=7) and saline mice 
(n=4) at 8 weeks post injection with the RNeasy Mini-Kit (Qiagen; Valencia, CA) 
according to manufacturer’s protocol. Extracted RNA was quantified with a 
Thermo Scientific NanoDrop 2000 (Cole-Parmer, Vernon Hills, IL) and cDNA was 
synthesized with 1 µg of total RNA (RT2 First-Strand Kit, SA Biosciences; 
Valencia, CA) and used as a template on an ABI 7900HT real-time PCR 
instrument (Applied Biosystems; Foster City, CA) using a RT2Sybr® Green/Rox 
qPCR Mastermix (SA Biosciences) in technical replicates of four. Target and 
reference gene amplification was performed separately using RT2 qPCR Primer 
Assays (Qiagen) as follows: fibronectin 1 (Fn1; Mm.193099) and glyceraldehyde 
3-phosphate dehydrogenase (Gapdh; Mm.343110). The RNA levels were 
quantified using the ΔΔCT method. Expression values obtained Fn1 primer 
assays were normalized to Gapdh expression values. Transcript levels are 




Running Wheel (RW). Spontaneous wheel running has been demonstrated to 
improve outcome following contusive thoracic spinal cord injury (SCI; Engesser-
Cesar et al., 2005; 2007). To assess potential segmental lumbar plasticity, EB-
injected mice were allowed free access to a running wheel for 5 weeks post-EB. 
Mice were initially exposed to the wheel for 3 days and returned to non-RW 
cages for 1 week prior to baseline testing to allow any pre-lesion treatment 
effects from the RW to dissipate. All EB-injected mice received identical post-
operative care and housing conditions for 1 week of recovery at which point they 
were randomly assigned to one of 3 groups: EB with a RW provided ad libitum 
(EB+RW; n=12), EB no RW single housed (EB single; n=9) and EB no RW 
multiple housed (EB multiple; n=10). The EB single group was included to control 
for potential effects of housing condition on recovery as EB+RW mice were 
individually housed. Saline treated mice were multiple housed throughout the 
experiment (n=7). Wheel turns were magnetically monitored and a digital counter 
recorded data using a VitalView acquisition system and ER4000 Transponders 
(MiniMitter; Bend, OR) and data exported to a spreadsheet where total distance 
per unit time per mouse were calculated. The inside of the wheels were modified 
with clear vinyl (Home Depot) to provide a flat running surface and attached with 
two bolts. This modification is necessary to ensure that the rungs on the wheel 
do not exacerbate post-injury dysfunction (Engesser-Cesar et al., 2005).  
 
Statistics. Left-right side differences were analyzed using paired t-tests where 
appropriate before proceeding with further statistical analyses with the right-left 
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mean values. A repeated measures ANOVA with the group factor on averaged 
right-left values was employed for BMS and modified BMS subscore data across 
time. All significant group effects were followed by Tukey HSD post-hoc t-tests. 
For all other statistical analyses, a one-way ANOVA was used followed by Tukey 
HSD post-hoc t-tests where appropriate. Correlations were calculated with 




EB Dose Response 
 
At 2 weeks post injection, EC staining of longitudinal sections revealed that 0.20 
mg/mL EB was the optimal dose for demyelination. The 0.15 mg/mL EB dose 
exhibited little to no demyelination and the 0.25 mg/mL dose severely damaged 
axons (data not shown). GFAP immunoreactivity at 2 weeks is restricted to the 
perimeter of the lesion (Fig. 2A-C) while EC stained cross sections confirmed the 
accuracy of the injections into the VWM (Fig. 2D-G). EM images reveal 
demyelinated axons which appear intact 2 weeks post-injection (Fig. 2H-J). 
 
Behavioral response to 0.20 mg/mL EB injection into the adult mouse VWM 
 
Bilateral injections of 0.20 mg/mL EB into the mouse VWM induces a chronic 
hindlimb deficit observed as a significant reduction in BMS scores compared to 
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controls (Fig. 3A). At 1 week post-EB, scores centered around 4 to 5, indicating 
the ability to plantar step with little to no coordination. This deficit recovered 
slightly until week 3 when BMS scores plateaued at approximately 6, indicating 
hindlimb coordination during overground locomotion. Subscores of all mice 
achieving a BMS score of 5 or above were also significantly lower in EB-injected 
mice as compared to controls (data not shown). EC staining revealed that at 2 
weeks and 8 weeks post-EB, SWM at the lesion epicenter was 28.00% and 
24.12% of saline injected mice, respectively. Terminal BMS scores plotted 
against SWM (% of saline) at the epicenter for animals receiving 0.15 (n=6), 0.20 
(n=11) or 0.25 mg/mL (n=5) EB showed a positive correlation (R2=0.7674; p< 
0.001, n=22). However, BMS scores and total SWM for the animals that received 
0.2 mg/ml EB showed no correlation due to the narrow range of BMS scores 
represented. Previous work in the rat has shown that demyelination within the 
VWM (VLF+VC) induces a chronic hindlimb impairment despite recovery of the 
ability to consistently weight support whereas complete loss of ventral white 
matter results in flaccid paralysis of the hindlimbs (Loy et al., 2002a,b). To 
specifically assess the role of ventral white matter in the mouse (Fig. 3B), 
regression analyses of all 0.20 mg/mL EB injected mice revealed a significant 
positive correlation between terminal BMS scores and spared VWM (R2 = 
0.2521, p < 0.05, n=19; Fig. 3C).  
 




At 8 weeks post-injection, there was a significant increase in epicenter 
inflammatory cells as compared to saline, suggesting that EB induces a chronic 
inflammatory response that remains unresolved for at least 2 months (Fig. 4A-C). 
This was accompanied by a significant 4.2-fold increase in epicenter Fn1 mRNA 
transcript levels at 8 weeks as compared to saline injected VWM (Fig. 4D).  
 
 
Chronic axonal patency after EB lesions in the VWM   
 
NF-M immunoreactivity of cross-sections was performed to quantify axon number 
and diameter at the injury epicenter. At 8 weeks there was a significant reduction 
in the number of axons/mm2 within the VWM to approximately 36% of saline 
controls (Fig. 5A-C). The mean equivalent diameters of the remaining NF-M 
labeled axons were significantly larger in EB-injected epicenters suggesting a 
preferential sparing of larger diameter axons (Fig. 5D). However, ultrastructural 
analysis of the lesion epicenter revealed that surviving axons were severely 
swollen at 6 weeks post-EB suggesting that swelling, as opposed to preferential 
sparing of large diameter axons, is a more likely interpretation of why the 
remaining axons appear larger (Fig. 5E-G). Taken together, these data suggest 
that in the mouse, remyelination ultimately fails due to axonal loss and 





Effect of spontaneous wheel running on hindlimb function post-EB  
 
Both saline and EB-injected mice averaged approximately 2.4 miles/day on the 
running wheel and this was no different from the average daily distance run 
during the pre-injury habituation period which is similar to the 2.4-3.8 miles/day 
previously reported (Adlard et al., 2005). There were also no differences in 
weight gained/lost or SWM with running (data not shown). The BMS scores at 1 
week post-injection for EB+RW mice were higher than either the EB single or 
multiple housed mice indicating that the EB+RW group received a less severe 
lesion (Fig. 6A). Therefore, we determined the change in BMS scores between 
week 1 and week 5 (BMS difference score), which revealed no significant 
difference between groups (Fig. 6B). Moreover, Treadscan® analysis revealed no 
significant RW-induced recovery. These data suggest that spontaneous wheel 
running does not improve functional outcome following chronic VWM 




EB-injection into the adult mouse VWM resulted in persistent demyelination and 
inflammation concomitant with axonal loss resulting in hindlimb dysfunction. RW-
induced hindlimb recovery was not observed with the BMS and Treadscan®. 
Although the inflammatory response and axonal loss differ in the rat and mouse, 
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the mouse is similar to other mammals in the functional redundancy of 
descending locomotor pathways.      
 
EB lesions in the mouse exhibit a much steeper dose-response curve as there is 
only a 0.1 mg/mL difference in concentration between little to no demyelination 
(0.15 mg/mL) and complete axon loss (0.25 mg/mL), whereas the rat exhibits a 
much wider range of concentrations between little demyelination and axon loss 
(Yajima and Suzuki, 1979; Graca and Blakemore, 1986; Crang and Blakemore, 
1991; Penderis et al., 2003). In the rat, EB demyelination of the VLF induced no 
behavioral deficits detectable using the Basso, Beattie, and Bresnahan (BBB) 
Scale (Loy et al., 2002a). However, when VLF demyelination was combined with 
either dorsal column/corticospinal tract, ventral column or dorsolateral funiculus 
demyelination, mean BBB scores dropped to 15.9, 12.7 and 11.1, respectively. 
Consistent with those data, in the mouse, a significant reduction in BMS scores 
was observed 1 week post VWM EB-injection (VLF+VC) and this deficit persisted 
out to at least 2 months (Fig. 3A). Talbott et al. (2005) found that the epicenter of 
a rat VLF EB-lesion exhibited a transient inflammatory response that was 
completely resolved by 1 month. In contrast, the current study found increased 
CD45 immunofluorescence (Fig. 4A-C), increased Fn1 mRNA levels (Fig. 4D) 
and increased CD11b immunofluorescence (data not shown) at the EB lesion 
epicenter in mice out to at least 2 months suggesting a persistent inflammatory 
response. This is a phenotypic characteristic of fibrocytes, blood-borne immune 
cells which express CD45, CD11b and FN1 while lacking other lymphocyte 
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specific markers (Sroga et al., 2003; Chesney and Bucala, 1997). Although 
differences in the inflammatory response between rats and mice have been 
previously suggested following spinal cord contusion (Sroga et al., 2003), this is 
the first evidence of this following EB-injection.      
 
In the rat, there is no evidence of axon loss following dorsal column EB-injection 
at concentrations appropriate for demyelination, despite repeated episodes of 
focal demyelination (Franklin and Blakemore, 2008; Penderis et al., 2003). 
However, NF-M immunofluorescence, as well as ultrastructural analysis of 
epicenter cross sections confirms that EB induces axon loss in the mouse VWM 
(Fig. 4A) and without remaining axons, remyelination ultimately fails. Axon loss is 
due to one of two possibilities. The first is that EB directly affected axons 
resulting in axonal death and subsequent inflammation independent of EB-
induced oligodendrocyte loss. The second possibility is that EB-induced glial loss 
resulted in inflammation which, in combination with loss of glial-derived axonal 
support, resulted in axonal loss. It is likely that both possibilities contribute to 
axonal loss in a reciprocal manner, but these data do not provide insight into 
which situation arises first. A better understanding of why axonal loss occurs 
would aid in explaining why this phenomenon is not seen in rats following VWM 
demyelination. Taken together, our findings of a chronic inflammatory response, 
axon loss and the lack of a SWM difference between 2 and 8 weeks post-
injection suggests that EB lesions in the mouse VWM are non-remyelinating. It 
cannot be determined if remyelination would have still failed without axon loss. 
50 
 
However, this scenario is unlikely using this model considering the steep dose-
response curve for EB in the mouse. Henceforth, establishing a demyelinating 
lesion which consistently eliminates glia without damaging axons may not be 
possible in the mouse using EB. 
 
Engesser-Cesar et al. (2005) demonstrated that spontaneous wheel running 
resulted in significant improvements in BMS scores following a dorsal thoracic 
spinal contusion. Given the permanent loss of descending ventral motor 
pathways and its concomitant behavioral deficit in the mouse, we hypothesized 
that spontaneous wheel running might partially restore hindlimb function of EB-
injected mice by enhancing plasticity of intrinsic lumbar circuitry independent of 
remyelination. This was not observed in either the BMS or Treadscan® which is 
more sensitive to milder injuries (Beare et al., 2009) suggesting differences in 
recovery between contusive SCI and VWM demyelination. The lack of additional 
improvement in the RW group may be due to inherent differences in the injury 
model (dorsal contusion vs ventral demyelination) and/or there may be a ceiling 
effect rendering RW training unable to provide recovery additional to the recovery 
provided by in-cage activity alone (Fouad et al., 2000; Kuerzi et al., 2010). If the 
latter explanation is correct, this suggests that the greater initial (i.e. 1 week) 
hindlimb function in EB lesioned mice allowed for high levels of in-cage activity 
regardless of RW status. Taken together, these data offer two suggestions. The 
first is that RW does not facilitate lumbar plasticity robust enough to induce 
recovery in mice following EB-induced VWM demyelination. The second is that 
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the RW is unable to improve hindlimb dysfunction in mice beyond what in-cage 
training alone achieves following ventral lesions which do not limit the initial 
capacity for extensive in-cage activity. A similar ceiling for in-cage training in the 
rat has been suggested with multiple additional training regimens (Fouad et al., 
2000; Magnuson et al., 2009; Alluin et al., 2011; Kuerzi et al., 2010).   
 
These data suggest that mice are similar to the rat and cat in the anatomical 
distribution and functional redundancy of descending locomotor pathways. There 
are two main polysynaptic pathways regulating the initiation of locomotion. The 
primary locomotor pathway originates in the mesencephalic locomotor region 
(MLR), projects to the medullary reticular formation (MedRF) and subsequently 
descends through the VLF where it terminates at the spinal locomotor centers 
(Noga et al., 1991; Noga et al., 2003; Jordan et al., 2008). The second originates 
in the pontomedullary locomotor region (PLR) and is suggested to integrate 
sensory trigeminal information from the propriospinal system with the spinal 
locomotor system (Noga et al., 1991). The PLR projects to the spinal locomotor 
centers either by converging with the MedRF-VLF pathway or via thedorsolateral 
funiculus (DLF; Noga et al., 1991; Noga et al., 2003). The work by Loy et al. 
(2002a) also suggests a role for the VC in locomotion as combined VLF-VC 
demyelination induced a significant behavioral deficit in rats which was greater 
than that seen following VLF demyelination alone, potentially by disrupting long 
propriospinal interneurons. Those data are consistent with the VWM lesions 
described here which resulted in chronic behavioral deficits suggesting that 
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multiple locomotor pathways have been lost. Moreover, once BMS scores 
plateaued at approximately week 3 (Fig. 3A), locomotion was mostly coordinated 
(as defined by BMS and Treadscan® analysis) suggesting the presence of 
secondary / tertiary locomotor pathways located within the dorsal and 
dorsolateral region of the spinal cord.  
 
Therefore, as in the rat and cat, the mouse has functionally redundant locomotor 
pathways able to compensate when other locomotor pathways are lost. However, 
as more descending motor pathways are lost, compensation becomes limited 
and locomotor impairments are observed. This is not surprising considering the 
conservation of these pathways across mammals and in birds (Jordan et al., 
2008; Noga et al., 1991; Loy et al., 2002a; Vilensky et al., 1992; Schucht et al., 
2002; Sholomenko and Steeves, 1987) and supports the importance of ventral 
pathways to locomotion suggesting that at least some VWM must be spared for 
compensation to occur. To our knowledge, this is the first description of ventral 
locomotor pathway function in mice. Given that infarction to the ventral portion of 
the cord (anterior cord syndrome; ACS) is far more common than infarction to the 
dorsal portion of the cord (posterior cord syndrome; PCS) following human SCI 
(Fehlings et al., 2012; Fulk et al., 2007; Schneider et al., 2010), the functional 
deficits observed with this VWM lesion may better-reflect what is observed 
clinically. Moreover, recovery from PCS is common while ACS related deficits are 
chronic as patients experience little recovery (Fehlings et al., 2012; Kirshblum 
and O’Conner, 1998; McKinley et al., 2007). Although these data support the use 
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of vental lesions in modeling human SCI, EB-induced VWM demyelination in the 
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Figure 2. IHC, EC staining and EM images assess astrocytic reactivity, 
demyelination and ultrastructural integrity, respectively. Longitudinal sections 
stained with Hoechst and GFAP to identify cell nuclei (A) and astrocytes (B), 
respectively, display GFAP immunoreactivity restricted to the perimeter of the 
lesion at 2 weeks post-0.20 mg/mL EB into the mouse VWM (C). Hoechst 
staining reveals a large number of nuclei within the lesion epicenter (A), which 
were later confirmed to be infiltrating inflammatory cells (Fig. 4). EC stained cross 
sections at the level of injection: Saline (D) and 0.20 mg/mL EB -1 mm (E), at the 
epicenter (F) and +1 mm (G). EM images of (H) naïve axons which display thick 
compact myelin sheaths and 0.20 mg/mL EB-injected VWM which reveal spared, 
demyelinated axons at 1 (I) and 2 (J) weeks post-injection. Scale bars in C and J 

























Figure 3. Functional and histological consequences of EB lesions. BMS scores 
reveal a significant hindlimb dysfunction which persists chronically following 
injection of 0.20 mg/mL EB into the mouse VWM (saline n=9; 0.20 mg/mL EB 
n=11; B). A positive correlation (C;R2=0.2591; p<0.05; n=19) exists when 
terminal BMS scores were plotted against ventral spared VWM (B) highlighting 
the importance of ventral white matter to hindlimb function following injection of 
0.20 mg/mL EB (C). Data in A are presented as mean ± standard deviation; *p< 






















Figure 4. Chronic inflammatory response following EB lesions. There was a 
significant increase in CD45+ expression within the EB-injected epicenter (A) as 
compared to saline (B) suggesting that EB induces a chronic inflammatory 
response that persists for at least 2 months post-injection (saline n=8, 0.20 
mg/mL EB n=9; C). This was accompanied by a significant 4.29-fold increase in 
epicenter Fn1 mRNA levels (normalized to Gapdh) at 8 weeks as compared to 
saline injected VWM (saline n=4, 0.20 mg/mL EB n=7; D). Adjacent EC images 
(upper right corner of A and B) were used to select ROIs within the VWM for 
CD45 IHC (A and B). Data in C and D are mean ± standard deviation; *p< 0.05; 





























Figure 5. Chronic axonal integrity following VWM EB lesions. NF-M expression at 
8 weeks (B) revealed a significant reduction in axons/mm2 within the VWM to 
approximately 36% of saline controls (saline n=8, 0.20 mg/mL EB n=9; C). Of the 
remaining NF-M labeled axons, mean equivalent diameters were significantly 
larger in EB-injected epicenters (D). Ultrastructural analysis revealed that 
compared to saline-injected (E) epicenters surviving axons after EB were 
severely swollen and much of the remaining myelin disorganized at both 3 (F) 
and 6 (G) weeks post-EB, accounting for the significant increase in spared axon 
diameter observed in D. Data in C and D are mean ± standard deviation; *p< 























Figure 6. Neither spontaneous wheel running nor group housing improves 
hindlimb function following injections of 0.20 mg/mL EB. EB+RW mice displayed 
less severe deficits prior to assignment to experimental condition (i.e. EB+RW, 
single or multiple housed; A). Difference scores (absolute value of week 1 BMS 
score – week 5 BMS score) similarly revealed no hindlimb recovery between EB-
injected groups (B). Data are means ± standard deviation, EB+RW, n=12; EB 







































CHARACTERIZING IN VIVO ELECTROPHYSIOLOGICAL ASSESSMENT IN 




Demyelination from contusive spinal cord injury (SCI) and diseases such as 
multiple sclerosis (MS) results in chronic functional (Waxman, 1989; Miller et al., 
2002). Injection of the gliotoxin ethidium bromide (EB) has been used extensively 
to model spinal cord demyelination in both rats and mice (Blakemore and 
Franklin, 2008; Kuypers et al., 2013; Fushimi & Shirabe, 2002; 2004). While 
oligodendrocyte (OL) loss is a hallmark characteristic observed within the 
epicenter of an EB lesion (Blakemore and Franklin, 2008), the absence of other 
glia and even some axonal loss can be observed as well (Talbott et al., 2005; 
Kuypers et al., 2013). This complicates data interpretation making it difficult to 
determine if the dysfunction observed is due to axonal or glial cell loss. 
Nevertheless, these studies have been instrumental in helping to identify the 
spinal white matter tracts responsible for particular aspects of locomotion (Loy et 
al., 2002a; Nichols et al., 2013; Kuypers et al., 2013) as well as assessing 
remyelination (Talbot et al., 2005; Talbott et al., 2007; Blakemore and Franklin,  
2008). Moreover, when combined with irradiation to prevent endogenous 
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remyelination, EB demyelination provides a platform to assess exogenous 
remyelination following engraftment of Schwann cells or pro-myelinating OL-
progenitors (Franklin et al., 1996; Hinks et al., 2001).  
 
The transcranial magnetic motor-evoked potential (tcMMEP) response (Linden et 
al., 1999) is a reliable functional assessment method commonly used to assess 
spinal cord conduction in EB-demyelinated (Loy et al., 2002a,b; Talbott et al., 
2005) and spinal contused  (Magnuson et al., 1999; Zhang et al., 2008) rats and 
spinal lacerated mice (Hill et al., 2010). The response is magnetically stimulated 
in the brainstem and descends through the spinal cord via the ventrolateral 
funiculus (VLF) where it synapses monosynaptically onto lower motor neurons 
controlling gastrocnemiums muscle contractions (Magnuson et al., 1999).  VLF 
integrity is assessed by using gastrocnemius muscle contraction intensity and 
latency as a proxy for tcMMEP response intensity and latency. The tcMMEP 
response is ablated by SCI (Magnuson et al., 1999), VLF demyelination (Loy et 
al., 2002a,b) and thoracic transection (Hill et al., 2010). However, following SCI 
tcMMEP responses have been shown to return in rats engrafted with 
oligodendrocyte precursor cells (Cao et al., 2010).  
 
All studies mentioned above involving tcMMEP assessment in rats have been 
performed with the commercially available Cadwell stimulator (Cadwell 
Laboratories, Kennewick, WA). There is only one published report of mouse 
tcMMEP response assessment (Hill et al., 2010). This study utilized descending 
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thoracic lacerations which resulted in reduced tcMMEP amplitude that decreased 
incrementally with lesion depth but this study used a customized Magstim 
stimulator (The Magstim Company, UK). Considering the unlimited genetic 
potential of mouse models, characterizing the use of a commercially available 
stimulator would facilitate standardization of tcMMEP assessment in mice across 
laboratories would provide a valuable tool to assess mouse remyelination in vivo. 
Therefore, we aimed to characterize both tcMMEP response assessment and the 
effect of EB-demyelination on tcMMEP responses in the adult mouse using the 
Cadwell stimulator. Unfortunately, following EB-demyelination, axon loss was 
more robust in mice than it is in rats making it impossible to discern whether loss 
of tcMMEP responses were due to demyelination or complete axonal severance 
(Kuypers et al., 2013). Moreover, the presence of the tcMMEP responses in EB-
demyelinated mice despite axonal loss suggested that the Cadwell stimulator 
might stimulate an alternate pathway in mice than it does in rats. To that end, we 
finally investigated the effect of descending thoracic transections and cervical 
lateral hemisections on tcMMEP responses recorded using a Cadwell stimulator 
determining that tcMMEP assessment in mice with the currently available 
commercial technology is unreliable.     
 
Materials and Methods 
 
Animal Care and General Surgical Procedures: All animal procedures were 
performed in strict accordance with the Public Health Service Policy on Humane 
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Care and Use of Laboratory Animals, Guide for the Care and Use of Laboratory 
Animals (Institute of Laboratory Animal Resources, National Research Council, 
1996), and with the approval of the University of Louisville Institutional Animal 
Care and Use Committee. Adult female C57Bl/6 mice were anaesthetized with 
2.0% avertin (2,2,2-tribromoethenol in 1.25% 2-methyl-2-butanol in saline), 
treated with 1cc sterile saline (s.c.) and lacrilube for the eyes. Body temperatures 
were maintained during all surgical and post-op procedures at 37-38°C. 
Following post-op suturing and care, mice were treated prophylactically with 
gentamycin and a second 1 cc bolus of sterile saline (s.c.) and placed in heated 
recovery cages with alpha-dry bedding. Buprenorphine (0.05 mg/kg) was 
administered twice daily for 48 hours. Soft food, additional subcutaneous saline 
injections and bladder expression was performed as needed (up to 2-3 
times/day). The animals were housed in ventilated cages (≤ 5 mice / cage) and 
provided ad libitum food and water. 
 
Ethidium Bromide (EB) Injections: Ethidium bromide injections were performed 
using a beveled glass micropipette (~25 um) driven by a Parker II picospritzer. 
After a laminectomy and durectomy at the T10 vertebral level, mice were placed 
in a stereotaxic device and two 0.25 µl boluses of either EB (0.20 mg/mL; N=13) 
or saline (N=9) spaced 1 minute apart were injected into 2 locations separated by 
1.5 mm rostro-caudally within the laminectomy. Injections were bilateral, 
approached at an 18° angle to a depth of 1.1 mm and centered 0.45 mm lateral 
from midline. This lesion produces a ventral column (VC) lesion encompassing 
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both the VLF and ventral funiculus (VF; Kuypers et al., 2013). Following 
injections, the needle was left in place for 3 minutes to allow the EB or saline to 
diffuse.  
 
Lacerations: Cervical lateral hemisections C5/C6 (N=4) and complete thoracic 
transections at T9/T10 (N=2) were performed as previously described (Hill et al., 
2010). Briefly, anesthetized mice were placed into a spinal column stabilizer and 
lacerations were made using the Louisville Injury System Apparatus with the 
Vibraknife attachment (LISA-Vibraknife; Louisville, KY). Only complete 
transection mice received a laminectomy. Both lacerations were produced at a 
depth of 1.6 mm with the lateral hemisection only extending to midline. Following 
each lesion, the spinal cord was assessed for additional damage to rule out the 
possibility of contusion. Musculature suturing was done with a 10-0 suture and 
the skin stapled with 9-mm metal suture clips (Becton Dickinson, Sparks, MD). 
 
Basso Mouse Scale (BMS) Assessment: The BMS assessed hindlimb function 
during open field locomotion in all lacerated mice. This scale is optimized to 
reliably assess mouse hindlimb function following SCI and other insults which 
compromise hindlimb function (Basso et al., 2006; Engesser-Cesar et al., 2005). 
BMS assessment was performed at baseline and at day 7 post-laceration. Mice 
were scored by two raters (trained at Ohio State University) blinded to the 
experimental condition. BMS scores range from 0–9 and subscores were not 
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calculated as none of the lesioned animals displayed scores above 5, which 
functionally corresponds to coordination.   
 
Electrophysiology: Transcranial magnetic motor evoked potentials (tcMMEPs) 
was used to examine conduction within the VLF bilaterally. Baseline conduction 
was assessed once preoperatively and weekly for 8 weeks following EB injection 
and at days 3, 7 and 10 post-laceration. Assessments were done in restrained, 
unanesthetized mice. The mice were restrained using a custom mouse restraint 
jacket designed by Lomir Biomedical Inc. Animals were lightly anesthetized with 
isoflurane to eliminate stress and facilitate fastening the animals into the restraint 
jacket. Animals were then placed back into their cages for 15 minutes and 
allowed to recover from anesthesia. A commercially available Cadwell 
Stimulator/recorder (MES-10, 2 tesla maximum output) attached to a 25 mm 
dual-coil hand held magnetic transducer was used for assessment of VLF 
conduction. The magnet was placed over the scalp and a 70 μs magnetic pulse 
was delivered while EMG responses were recorded from needle electrodes 
inserted bilaterally into the gastrocnemius muscle. Reference electrodes were 
placed into the distal tendon of the gastrocnemius muscle and a ground 
electrode was place sub-cutaneously above the base of the tail. Magnet intensity 
was set at 100% across all mice as intensities of 80% and 90% yielded lower 
amplitude responses suggesting that the ceiling of axonal recruitment has not 
been maximally reached. The onset latency was measured in milliseconds 
(msec) and the peak-trough amplitude was measured in millivolts (mV). The 
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signal-to-noise ratio was set at 5 times the level of background noise and 
recordings with amplitudes less than this were considered noise. The procedure 
takes only a few minutes and does not appear to be painful to the animals, as 
they tolerate the restraint well and do not show signs of discomfort during the 
stimulation and recording procedures. Following testing and in between animals, 
mice were placed into a new clean cage with topical administration of bacitracin 
to the puncture wounds while electrodes were cleaned and sharpened. Restraint 
jackets were washed between testing sessions.  
 
Tissue Processing: Mice were sacrificed with an overdose of avertin (2.0%) and 
transcardially perfused with cold phosphate buffered saline (PBS) until the liver 
was clear and fixed with cold 4% paraformaldehyde (PFA). Spinal cords were 
dissected and allowed to post-fix for 24 hours in 4% PFA cryoprotected in 30% 
sucrose in PBS for 72 hours. Spinal cords were blocked in tissue freezing 
medium (Triangle Biomedical Sciences, Durham, NC) and frozen at -20°C prior 
to sectioning at cryostat (20um). Sections were transferred to coated slides and 
stored at -20°C.     
 
Eriochrome Cyanine (EC) Staining: Tissue sections were stained EC to 
distinguish myelinated from unmyelinated spinal cord throughout the lesion. The 
percentage of total white matter in EB injected mice relative to saline injected 
control mice was adapted from a protocol formerly described in rats (Magnuson 
et al., 2005). Briefly, slides were allowed to thaw at room temperature for 20 min. 
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Then, sections were hydrated by submersion in xylene (60 min) and hydrated by 
submersion in 100% ethanol (3 min), 95% ethanol (3 min), 70% ethanol (3 min), 
50% ethanol (3 min), and distilled water (2 min). Slides were then stained with 
EC for 10 min. After rinsing in distilled water (x 2) to wash excess EC, sections 
were differentiated in 0.5% ammonium hydroxide solution for 30 sec, followed by 
2 more distilled water washes. Sections were air dried overnight at room 
temperature, cover-slipped the next day and again dried overnight at which point 
the tissue was ready for imaging. Brightfield images were captured with a Nikon 
Eclipse TE 300 inverted microscope and a spot CCD camera. White matter was 
traced with Nikon Elements software and epicenters were defined as the 
segment(s) with the least spared white matter. 
 
Statistics: We checked for left-right side differences using paired t-tests where 
appropriate before proceeding with further statistical analyses with the right-left 
mean values. A repeated measures analysis of variance (ANOVA) with the group 
factor on averaged right-left values was employed for BMS, modified BMS 
subscore, tcMMEP amplitude and latency data across time. All significant group 
effects were followed by Tukey HSD post-hoc t-tests. At week one, EB+RW 
displayed a higher BMS score as compared to other EB injected groups 
suggesting that group received less severe injuries as RW treatment did not 
begin until 1 week post-EB. Therefore, absolute values of the difference score 
between weeks 1 and 5 to assess recovery following induction of wheel running. 
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For all other statistical analyses, a one-way ANOVA was used followed by Tukey 






Open field locomotor assessment was performed at baseline and at days 2 and 7 
post-laceration. Complete transection mice all displayed BMS scores of 0-1 at 2 
and 7 days post injury which functionally corresponds to flaccid hindlimb 
paralysis with an occasional spasm and absolutely no weight barring (data not 
shown). Lateral hemisection mice displayed unilateral paralysis in the limb 
ipsilateral to the lesion. In unilaterally injured mice with the ability to achieve 
coordinated open field locomotion (scores above 5), the BMS is not an 
appropriate measure of hindlimb dysfunction as assessment requires 
simultaneous assessment of all 4 limbs making it more suited for bilateral 
injuries. However, in severely injured mice lacking the ability to coordinate (BMS 
scores 5), the BMS can be used to assess hindlimb dysfunction unilaterally 
without accounting for the unaffected limb. Therefore, in the unilateral injured 
lateral hemisection group, the BMS was used to assess dysfunction in the limb 
ipsilateral to the lesion. These mice displayed complete flaccid paralysis (BMS 
scores of 0-1) in the affected limb and BMS scores of 2-4 for the unaffected limb. 
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By day 7, no noticeable dysfunction was present in the unaffected limb while 




Trans cranial magnetic motor evoked potential (tcMMEP) responses were 
assessed as previously described in rats (Loy et al., 2002; Talbott et al., 2005). 
Following bilateral EB-injection into the VC, no differences were found when 
comparing baseline tcMMEP amplitude and latency to responses attained 
following EB-injection. No changes were present within group across time for 
either amplitude or latency (Fig. 7A,B). There was no significant correlation for 
either amplitude or latency verse terminal BMS score suggesting that functional 
outcome following EB-injection had no relationship with tcMMEP amplitudes or 
latencies.  
  
Lateral hemisections and complete transections 
 
Considering the lack of a clear difference for either amplitude or latency in the 
saline group as compared to any EB-injected group raised concern as to the 
interpretability of the tcMMEP data. Therefore, we performed laceration 
experiments to confirm that the observed responses in EB-injected mice were in 
fact tcMMEP responses. Complete transections displayed no tcMMEP responses 
at 3 days posy injury (dpi), but responses began to return by 7 dpi and were no 
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different than baseline responses at 10 dpi (Fig. 8A). Similarly, ipsilateral 
tcMMEP responses in the lateral transected mice were abolished by 3dpi but 
were indistinguishable from contralateral responses at 10 dpi while contralateral 
responses remained at all time-points following lateral transection (Fig. 8B). We 
interpret these data as artifact and not evidence of restored spinal cord 
conduction but rather evidence of a potential extraspinal pathway which may or 
may not initiate in the spinal cord, can circumnavigate the lesion site and re-enter 
the cord below the level of the lesion yielding motor evoked potentials in the 
musculature. Spinal shock post-transection or lateral transection would also 
explain the temporary abolishment of the tcMMEP responses at the 3 dpi time-
points and as spinal shock resolves between 5 and 10 dpi, the responses return. 
Moreover, considering that conduction latencies were not statistically different at 
baseline testing  as compared to any post-transection time-point, it is likely that 
we are observing tcMMEP responses being conducted outside of the spinal cord 
in uninjured mice. Therefore, we have determined tcMMEP response 
assessment in awake, adult mice using a commercially available magnetic 
stimulator as unreliable. 
 
White matter sparing (WMS) and gross spinal cord anatomy 
 
EC staining of spinal cord cross sections throughout the lesion confirmed that the 
EB injections were accurate and demyelination was targeted to the VC (Fig. 7C). 
No residual white matter remained in completely transected mice or within the 
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lesioned hemisphere of lateral hemisection mice (data not shown). Moreover, 
gross anatomy of dissected spinal cords revealed that laceration lesions did not 




Assessing tcMMEP responses in mice with the currently available technology is 
unreliable. Although reference electrodes demonstrated gastrocnemius muscle 
contractility with response latencies and amplitudes that resemble tcMMEP 
responses (Fig. 7), they were maintained in both lateral hemisected (Fig. 8A) and 
complete transected mice (Fig. 8B). One possible explanation could be that 
unlike the rat, the small size of the mouse makes it difficult to target the magnetic 
stimulation to only subcortical areas. This could manifest in one of three ways: 1. 
Collateral stimulation of the lower motor neurons directly; 2. Collateral stimulation 
of the muscle directly; 3. Collateral stimulation of the recording electrode directly. 
As a positive control to recording electrode placement, the magnetic stimulator 
was placed below the level of EB or saline injection eliciting a high amplitude 
response approximately 2.0 ms in latency (data not shown). This confirmed that 
electrode placement was in fact in the gastrocnemius muscle for animals lacking 
a response.  However, this also confirmed that responses obtained by stimulating 
subcortically could not be explained by any of the possibilities mentioned above. 
A latency of 2.0 ms would be appropriate for the short, monosynaptic lower motor 
neuron – gastrocnemius pathway. Moreover, a latency acquired by directly 
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stimulating the muscle or recording electrode would be shorter than a latency 
acquired by directly stimulating the lower motor neuron directly. Thus, 
considering that responses acquired when stimulating subcortically displayed 
latencies of at least 5.0 ms (Fig. 7B), this eliminates the possibility that 
subcortically elicited responses were due to unintentional stimulation of other 
anatomical structures or recording electrodes directly.      
 
Another possible explanation is that magnetic stimulation does elicit a response 
which originates subcortically, but as the response descends down the spinal 
cord, it exits the spinal cord to traverse the site of the lesion before entering back 
into the spinal cord below the lesion. One possible extraspinal bridge could be 
the sympathetic chain ganglia which reside in close proximity to the ventral spinal 
cord. However, these pathways would be multisynaptic, potentially following a 
complex and fortuitous route extraspinally before entering back into the cord 
below the lesion. Both the number of synapses and increased distance travelled 
of extraspinal responses suggest that response latencies would be greater than 
what we report here eliminating extraspinal conduction pathways as an 
explanation. 
 
A second possibility is that the magnetic stimulation is stimulating axial 
musculature rather than particular anatomical loci within subcortical white matter. 
Axial musculature in the mouse is anterolaterally contiguous along the dorsal 
aspect of the torso and hindlimbs. Therefore, magnetic stimulation of axial 
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musculature could elicit a response which traverses down to the gastrocnemius 
muscle thus initiating a contraction. In both cases (chain ganglia and axial 
musculature), the methods required to assess this would are invasive when 
considering that responses would need to be assessed in fully awake animals as 
anesthesia can interfere with conduction. Electrophysiological assessment would 
need to be performed prior to, immediately after surgical dissection of the 
extraspinal pathways and then assessed over time to truly determine if 
responses are abolished. Therefore, until more mouse specific tcMMEP 
response assessment technology is commercially available, it will be challenging 
to interpret results across laboratories suggesting the presence of a tcMMEP 




We thank Darlene Burke for assistance with statistical analyses, Kariena Andres 
for animal care, Ping Zhang and Christine Yarberry for surgical support, Kim 
Cash for post-operative animal care, Johnny Morehouse for assistance with BMS 
assessment and William DeVries, Monica Vetter, Kurtis James and Minh Tran for 
assistance with tissue processing, histology and image quantification. Supported 
by NS054708, RR15576/GM103507, Norton Healthcare, Friends for Michael, 
Kentucky Spinal Cord and Head Injury Research Trust, and the Commonwealth 













Figure 7. Mouse tcMMEP response assessment. No changes were present 
within group across time for either amplitude (A) or latency (B) suggesting that 
functional outcome following EB-injection had no relationship with tcMMEP 





























Figure 8. Spinal cord laceration does not abolish subcortically-elicited MMEP 
responses. Ipsilateral subcortically-elicited MMEP responses in laterally 
hemisected mice were abolished by 3 days post injury (dpi) but were 
indistinguishable from contralateral responses at 10 dpi while contralateral 
responses remained at all time-points following lateral hemisection (A). Gross 
anatomical images in left column are of 2 laterally hemisected mice (A). Similarly, 
complete transections displayed no subcortically-elicited MMEP responses at 3 
days posy injury (dpi), but responses began to return by 7 dpi and were no 
different than baseline responses at 10 dpi (B). Gross anatomical images in right 


































CHARACTERIZING SFMBT2 CLUSTER MICRORNA (MIRNA) MIR-297C 
EXPRESSION INCREASES DURING MOUSE OLIGODENDROCYTE 
PROGENITOR (OP) DIFFERENTIATION AND REGULATES CELL CYCLE IN 
VITRO  
 
Introduction   
 
Oligodendrocytes (OLs) are the only source of myelin in the central nervous 
system (CNS) and their loss is partially responsible for the dysfunctional 
outcomes observed in multiple sclerosis (MS; Miller et al., 2000), the 
leukodystrophies (Perlman and Mar, 2012) and spinal cord injury (SCI; Waxman, 
1989). Although remyelination has been documented in human MS patients 
(Patrikios et al., 2006), it rarely is complete (Bramow et al., 2010). Central 
remyelination is driven by OL progenitors (OPs) which remain mitotically 
competent within the mammalian CNS throughout adulthood with the ability to 
respond to normal OL loss thus maintaining myelin levels (Franklin and ffrench-
Constant, 2008). However, following extensive trauma- or disease-induced 
demyelination, the number of OPs required to maintain functional myelin levels 
outweighs the number of OPs present and therefore many strategies have been 
attempted to increase OP numbers and enhance remyelination (Goldman and 
Windrem, 2006). The transcriptional events that regulate oligodendroglia during 
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remyelination are well understood as key regulatory elements such as Olig, Nkx, 
and Sox transcription factors have been identified (Wegner, 2008). However, 
since the recent discovery of miRNAs, it has become more clear that post-
transcriptional events are equally important to oligodendroglial translational 
regulation (Emery, 2010; Barca-Mayo and Lu, 2012; He et al., 2012). MicroRNAs 
(miRNAs) are class of ~22-33 nucleotide non-coding RNAs which by their short 
nature, target tens to thousands of mRNAs for degradation or translational 
repression thus preventing protein production (Chen and Rajewsky, 2007; Bartel, 
2009). Since the development of technologies to assay miRNA expression levels, 
multiple laboratories have identified miRNAs involved in remyelination in vitro 
(Lau et al., 2008; Dugas et al., 2010; Zhao et al., 2010). However, no data to 
date has identified oligodendroglial-specific miRNAs in vivo.  
 
Here, we describe a method which allows for the direct isolation of miRNAs from 
callosal OPs isolated in vivo and assessment of their expression levels during 
de- and re-myelination. Oxalic bis-cyclohexylidenehydrazide (cuprizone) is a 
copper chelator which can be administered to mice in chow to induce CNS 
demyelination, most notably in the corpus callosum (Steelman et al., 2008). The 
cuprizone model has been well described and is commonly employed as a 6 
week on cuprizone ingestion period (demyelination) followed by a 6 week 
recovery period (remyelination) where mice are returned to normal chow 
(Torkildsen et al., 2008). This remyelination response is driven by OPs and is 
observed during both the later part of the ingestion phase and throughout the 
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recovery (Mason et al., 2001; Matsushima and Morell, 2001). We hypothesized 
that miRNA changes within OPs would accompany the remyelination response 
both during and following cuprizone ingestion. Using transgenic mice with an 
enhanced green fluorescent protein (EGFP)-gene inserted downstream of both 
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNPase) promoters, CNPase-
EGFP expressing OPs were isolated from the white matter of mice during 
cuprizone-induced de- and re-myelination and corresponding miRNA expression 
levels were analyzed via microarray. Compared to callosal miRNA expression 
levels from normal mice, hundreds of miRNAs followed dynamic expression 
profiles which changed significantly across cuprizone treatment conditions. We 
identified novel miRNAs from the Sfmbt2 cluster which were demonstrated to 
regulate cell cycle entry.  
 
Material and Methods 
 
Animals. All animal procedures were performed in strict accordance with the 
Public Health Service Policy on Humane Care and Use of Laboratory Animals, 
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 
Re-sources, National Research Council, 1996), and with the approval of the 
University of Louisville Institutional Animal Care and Use Committee and 
Institutional Biosafety Committee. CNPase-EGFP± mice were received from the 
laboratory of Dr. Vittorio Gallo (George Washington University, DC). These mice 
have the EGFP gene inserted downstream of both CNPase promoters, C1 and 
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C2 (Yuan et al., 2002), which has been well described as being enriched within 
oligodendroglia (Vogel et al., 1988). For all experiments, both male and female 
mice ages 8 to 10 weeks were used.   
 
Husbandry and Genotyping. CNPase-EGFP colonies were maintained on a 
C57Bl/6 background while experimental mice were acquired by interbreeding a 
homozygous sire with a heterozygous dam whose progeny are referred to as 
CNPase+. For genotyping, a tail sample from each pup was digested with 
proteinase K in buffer (Sigma, St. Louis, MO) at 55 °C overnight. The following 
morning, DNA was extracted using the Phire Animal Tissue Direct PCR Kit 
(Thermo Scientific, Waltham, MA) and DNA yields were estimated with a 
NanoDrop 5000 machine (NanoDrop, Wilmington, DE) with DNA elution buffer 
used as a blank. A polymerase chain reaction (PCR) of genomic DNA was 
performed using forward (5’ – GGTGGTGCCCATCCTGGTCGAGC – 3’) and 
reverse (5’ – CCAGCATGCCTGCTATTGTCTTCCC – 3’) primers (Invitrogen, 
Grand Island, NY) which were designed based on the EGFP coding sequence. 
Final PCR product was electrophoretically separated on a 5% agarose gel and 
visualized with ethidium bromide. All CNPase+ pups were weaned at 3 weeks 
and housed with CNPase+ littermates and other age/sex matched CNPase+ 
litters for at least 5 weeks (8 weeks of age) before being included in the study. 
 
Cuprizone Treatment. Age and weight matched male and female mice were fed 
ad libitum a diet of 0.2% (w/w) oxalic bis-cyclohexylidenehydrazide (cuprizone; 
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Sigma-Aldrich, Milwaukee, WI) mixed into normal chow (Harlan Teklad, Madison, 
WI) beginning at 8 weeks of age. CNPase+ mice were distributed into 6 treatment 
groups as follows: 1 and 2 (no cuprizone at 8 and 20 weeks of age); 3 and 4 (3 
and 6 weeks of cuprizone diet); 5 and 6 (6 weeks of cuprizone diet followed by 3 
and 6 weeks recovery on normal chow). Two control groups were included to 
account for any age related differences in miRNA expression as the length of the 
cuprizone treatment regimen is considerable. Any miRNAs identified as being 
significantly different between the 8 week and 20 week old control groups were 
ruled out for further consideration as they may play a role in aging. For all other 
comparisons between experimental and control cuprizone groups, the control 
used was the 8 week group.   
 
Tissue Processing. Mice were sacrificed with an overdose of 2.0% avertin (2,2,2-
tribromoethanol) in sterile saline administered i.p. prior to transcardial perfusion 
with cold phosphate buffered saline (PBS) until the liver was clear and 
subsequent fixation with cold 4% paraformaldehyde (PFA). Following fixation, 
brains were removed and post fixed for 24 hours in 4% PFA. Cryoprotection was 
performed by immersion into a 30% sucrose solution for at least 72 hours at 4 
°C. Brains were blocked in tissue freezing medium (Triangle Biomedical 
Sciences, Durham, NC) and frozen at −20 °C prior to coronal sectioning with a 
Leica cryostat (Buffalo Grove, IL) at 30 μm. Tissue sections were transferred to 




IHC. To distinguish CNPase+ expressing cells from neurons and other glia, 
sections were stained with primary antibodies against glial fibrillary acidic protein 
(GFAP) to identify astrocytes (Fig. 9B), neurofilament medium (NF-M) to identify 
neurons (Fig. 9C) and CNPase to identify oligodendroglial lineage cells (Fig. 9A). 
Staining protocols were as follows: tissue sections were blocked with 5% BSA, 
10% normal donkey serum (NDS), and 0.1% Triton-X-100 in Tris-buffered saline 
(TBS) for 1 h at room temperature. Primary polyclonal antibodies NF-M (rabbit, 
1:250, Millipore; Billerica, MA), GFAP (rabbit, 1:500, Dako; Carpinteria, CA), 
CNPase (rabbit, 1:250, Sigma) were incubated for 24 h at 4 °C with 5% BSA, 5% 
NDS, and 0.1% Triton-X-100 in TBS. Sections were next washed at room 
temperature (× 3) with TBS and incubated with fluorescein (FITC; 1:200) or 
rhodamine (TRITC; 1:200)-conjugated F(ab′)2 secondary antibodies (donkey, 
Jackson ImmunoResearch; West Grove, PA) for 1 h at room temperature. 
Species-specific IgG isotype controls were used to account for any non-specific 
binding or other cellular protein interactions. Hoechst™ was used to identify 
nuclei. Fluorescent imaging was done on a Nikon Eclipse TE 300 inverted 
microscope with a spot CCD camera. Exposure times remained identical across 
all images. Endogenous CNPase-EGFP reporter expression was co-localized 
with polyclonal CNPase expression as confirmation that endogenous expression 
is sufficient to label oligodendroglia (data not shown). Callosal regions of interest 
(ROIs) were selected in serial cross sections by tracing the corpus callosum from 
midline to the lateral extent of corpus callosum -2.00 mm behind bregma (area 
outlined and labeled as C.C.; Fig. 9D,E,F). Bilateral EGFP intensity within the 
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selected ROI of CNPase+ brains compared to CNPase- callosal EGFP intensity 
was used to estimate the relative decrease and return in CNPase expressing 
oligodendroglia during cuprizone de- and re-myelination, respectively (Fig. 9G). 
ROI selection and EGFP intensity quantification was done with Elements 
software (Nikon) and student t-tests were performed (Fig. 9G). Data are 
presented as mean ± standard deviation (n = 3/ cuprizone treatment condition 
assessed). 
 
Callosal Dissection and Tissue Dissociation. In total, 207 CNPase+ mice were 
used for miRNA microarray experiments. A sample from at least 2 wild type (WT) 
mice subject to the same dissection and digestion protocol served as a negative 
control to EGFP expression in fluorescence activated cells sorting (FACS) 
experiments. The corpus callosi of 10 to 15 mice within the same experimental 
group were pooled to yield an n = 1. This was replicated in separate experiments 
to obtain an n = 3. Mice were anesthetized with 2.0% avertin in sterile saline 
administered i.p. prior to transcardial perfusion with cold phosphate buffered 
saline (PBS). Following perfusion, brains were removed and the corpus callosum 
from bregma to -2.5 mm bregma was dissected away from surrounding cortical 
and striatal tissue in cold HBSS lacking calcium and magnesium (Invitrogen,). 
Following dissection, corpus callosi were homogenized by hand using a razor 
blade in 1 mL fresh HBSS. Tissue homogenates were collected into a 15 mL 
conical tube and digested for 15 minutes at 37 °C in enzyme mix 1 of the Neural 
Dissociation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Following 
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mechanical dissociation with a wide bore fire polished Pasteur pipette, samples 
were digested with enzyme mix 2 of the Neural Dissociation Kit for 10 minutes at 
37 °C with gentle agitation. Next, tissue was further mechanically dissociated 
with a medium and small bore fire polished Pasteur pipette, successively, sieved 
through a 40 µm cell strainer (BD Falcon, Bedford, MA) and then incubated at 
37°C for an additional 10 minutes prior to centrifugation with agitation. Single cell 
number was counted with a hemocytometer. The cell suspension was diluted 1:5 
in cold HBSS with calcium and magnesium (Invitrogen) and centrifuged for 10 
minutes at 300 g. Cell pellets were re-suspended in 8.5 mL MACS buffer stock 
(Miltenyi Biotec) containing 5% bovine serum albumin (BSA) and ??mg/mL 
insulin which was added to 5.7 mL of 90% percoll (Sigma) in 10x HBSS and 
centrifuged at 15,000 g for 15 minutes to remove myelin. Following 
centrifugation, myelin was aspirated from the top and the middle glial layer of 
cells was removed and centrifuged at 1200 g for 10 minutes to remove the 
percoll. Cells were washed twice and resuspended in a final volume of 0.5 mL 
MACS buffer containing BSA and insulin in preparation for FACS-based 
experiments.     
 
FACS. Glial layer samples were subjected to FACS using a MoFlo system 
(DAKO, Ft. Collins, CO). Cells remained on ice throughout all sorting 
experiments. The samples were loaded and event flow was established. The 
triggering setting was reconfigured from cell size to fluorescence. Real time 
analysis of the pulse width versus forward scatter allowed for exclusion of 
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doublets. Event triggering was based on the fluorescence of endogenous EGFP 
reporter or CD45-conjugated peridinin chlorophyll protein (perCP) fluorescence 
at an excitation of 488 nm and detection at 530/40 nm and 678 nm, respectively. 
Callosal tissue from WT mice was used as a negative control for EGFP 
expression and the IgG isoltype-conjugated perCP control to established 
background perCP expression and the gating parameters. A bright cell 
population (gate R3; Fig. 10A) was consistently present above background in all 
samples and was 52.34% ± 7.45% (± standard deviation) of total sorted events 
(gate R1; Fig. 10A). To assess the presence of any myeloid lineage cells in 
sorted populations, un-sorted cell suspensions were incubated with either an 
antibody against common leukocyte surface antigen CD45 conjugated to perCP 
(1:100; BD Biosciences, San Jose, CA) or a perCP-conjugated IgG isotype 
control antibody (1:100; BD Biosciences) for 30 minutes at 37 °C in culture media 
and washed 1 x with DPBS prior to final re-suspension in cold DPBS for sorting.   
 
Microarray. Following sorting, all samples were maintained at 4 °C throughout. 
Sorted cells were centrifuged at 300 g for 10 minutes and supernatant was 
aspirated. Total RNA was extracted from cell pellets immediately following 
sorting using the mirVana™ miRNA Isolation Kit (Invotrogen) as per the 
manufacturers protocol for cells in suspension. Once eluted from the column, 
total RNA was immediately frozen and stored at -80 °C. Once all microarray 
samples were collected (n = 3/ group), samples were shipped on dry ice to 
Exiqon (Woburn, MA) where a single color genome wide miRNA expression 
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profile analysis was performed using miRCURY LNA™ miRNA Arrays. Exiqon 
performed all miRNA quality control, extraction, enrichment and normalization 
and data were received as expression values above background. Principal 
component analysis (PCA) was performed with the statistics package R ([public 
domain] http://www.r-project.org). Differentially expressed miRNAs were 
identified statistically by group ANOVAs performed across cuprizone treatment 
conditions with Benjamini Hochberg correction for false discovery rate (FDR; 
Pawitan et al., 2005). Unsupervised hierarchical clustering was performed with 
Cluster 3.0 ([public domain] rana.lbl.gov/EisenSoftware.htm) using the average 
linkage method (Eisen et al., 1998).  
 
qRT-PCR. All qRT-PCR experiments were performed with an ABI 7900HT real-
time PCR instrument (Invitrogen). Gene amplification for all mRNA and miRNA 
experiments was performed with pre-designed primer assays (Qiagen, Valencia, 
CA) and 20x Taqman® miRNA primer assays (Invitrogen), respectively. RNA 
concentrations were estimated with a NanoDrop 5000 machine with RNA elution 
buffer as a blank. First strand synthesis of complimentary DNA (cDNA) was 
performed using the RT2 First Strand Kit and RT2 SYBR® Green ROX Master Mix 
(both from Qiagen) was used for cDNA detection. miRNA reverse transcription 
(RT) was performed with the TaqMan® MicroRNA Reverse Transcription Kit 
(Invitrogen) in combination with 5x miRNA-specific RT-primers and qRT-PCR 
analysis was performed by adding miRNA-RT product to Taqman® universal 
PCR master mix (Invitrogen). Target and reference gene amplification was 
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performed in separate tubes and run in triplicate. Mouse specific primer assays 
used in combination with RT2 SYBR® Green ROX Master Mix are as follows: 
Oligodendrocyte transcription factor 2 (Olig2; PPM04752B), platelet-derived 
growth factor receptor alpha (PDGFRα; PPM03640D), proteolipid protein 1 
(PLP1; PPM04717C) and glyceraldehyde-3-phosphate dehydrogenase (Gapdh; 
PPM02946E; all purchased as pre-designed primer sets from Qiagen) while 
custom Invitrogen primers were used to access gene expression levels for myelin 
basic protein (MBP; forward primer 5’ – GCCCATTGGTACACACTAAC – 3’and 
reverse primer 5’ – CTCGATTCAGTGACAGGAAC – 3’) , glial fibrillary acidic 
protein (GFAP; forward primer 5’ – TCCTGGAACAGCAAAACAAG  – 3’and 
reverse primer 5’ – CAGCCTCAGGTTGGTTTCAT – 3’), microtubule associated 
protein 2 (Map 2; forward primer 5’ – GAACTGACTCTCTCTGGATCTG  – 3’and 
reverse primer 5’ – ACCTTCAGCCAAACTGAGC  – 3’). Taqman® 20x miRNA 
primer assays were as follows: mmu-miR-338-5’, mmu-miR-297c-5’, U6 small 
nucleolar RNA (U6 snRNA) and small nucleolar RNA 135 (snoRNA 135; all 
purchased from Invitrogen). RNA levels were quantified using the delta-delta CT 
(ΔΔCT) method. Expression values from triplicate runs were normalized to 
reference gene triplicate values (Gapdh for SYBR® Green ROX based 
experiments and U6 snRNA or snoRNA135 for miRNA based experiments). 
Transcript levels are reported as fold change compared to normalized calibration 
sample gene expression. A one-way analysis of variance (ANOVA) was used to 




OP Isolation from Mouse Pup Cortex. The cortices of both male and female 
postnatal day 5 (P5) C57Bl/6 mouse pup cortices were dissected away from 
whole brain as previously described (Dincman et al., 2012). Briefly, tissue was 
dissociated using the Neural Tissue Dissociation Kit (Miltenyi Biotec) according 
to the manufacturer's protocol. Following dissociation, the entire cell suspension 
was incubated for 7 minutes at 4 °C with a mouse O4 hybridoma supernatant 
containing antibodies which recognize the O4 sulfatide. Following incubation, 
cells were washed and incubated with rat anti-mouse IgM magnetic beads (10% 
diluted in MACS buffer; Miltenyi Biotec,) which bind only to O4+ cells within the 
suspension. Following two washes, the magnetically bound cell are maintained in 
the column while all O4- cells are eluted and discarded. Between 8,000 and 
12,000 cells/cm2 were finally eluted into a pre-equilibrated 10 cm tissue culture 
dish coated with poly-D-lysine (PDL) and laminin (both from Sigma) containing 
mouse OPC-A (mOPC-A) medium which was prepared as follows: Add 2.1 g/L 
NaHCO3 (Sigma) to DMEM-F12 lacking HEPES (Invitrogen) and supplement with 
1 x N2, 2 x B27, 1% penicillin/streptomycin (all from Invitrogen), BSA (0.01%, 
Sigma), 40 ng/ml FGF2 (Millipore, Billerica, MA), and 20 ng/ml PDGFαα (Sigma). 
Average OP yield was 8–10 × 106 cells/brain with 85–95% viability. Following 
isolation, cells were incubated at 37 °C with 5% CO2. 
 
Cell Culture. Following final cell elution into the pre-equilibrated 10 cm tissue 
culture dish (passage 0; P0), cells were maintained in mOPCa medium for 24 
hours and incubated at 37 °C with 5% CO2. To assess the role of miRNAs 
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identified via microarray in differentiating primary OPs, cells were exposed 
following the 24 hour post-elution incubation period to either mOPCa medium to 
drive proliferation or mOPC differentiation medium for 72 hours. mOPC 
differentiation medium was prepared as follows: Add 2.1 g/L NaHCO3 (Sigma) to 
DMEM-F12 lacking HEPES (Invitrogen) and supplement with 1 x N2, 2 x B27, 
1% penicillin/streptomycin (all from Invitrogen), BSA (0.01%) and T3 (40 ng/mL; 
both from Sigma). Following experimental condition assignment and the 72 hour 
differentiation or proliferation period, total RNA was collected from each plate. 
Total RNA was also collected immediately following the 24 hour post-elution 
time-point from a subset of plates to serve as a calibration control for qRT-PCR 
experiments. A single plate is considered n = 1 and each condition (72 hours 
mOPCa medium, 72 hours mOPC differentiation medium or the 24 hour mOPCa 
medium calibration sample) was replicated to achieve n = 4 for qRT-PCR based 
experiments and n = 2 for immunocytochemical (ICC) assessment of 
oligodendroglial differentiation markers.   
 
Multiple miRNAs identified via microarray were screened in vitro with qRT-PCR 
following primary OP proliferation or differentiation. One miRNA was found to be 
consistently upregulated during primary OP differentiation versus OP 
proliferation; miR-297c. Therefore, to further assess the regulatory role for miR-
297c, gain and loss of function assays were performed by transfecting miRNA 
mimics or inhibitors (Invitrogen). Due to the high sensitivity of primary mOPCs to 
transfection reagent toxicity, miRNA mimic/inhibitor transfection was unable to 
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achieve an acceptable transfection efficiency using non-toxic transfection reagent 
concentrations. Therefore, miRNA mimic/inhibitor gain and loss assays were 
performed using mouse embryonic fibroblasts (MEFs; SCRC-1040; ATCC, 
Manassas, VA) as they are more tolerant to higher transfection reagent 
concentrations. P0 MEFs were expanded for at least 2 passages in 10 cm tissue 
culture dishes lacking a substrate coating in MEF expansion medium which was 
prepared as follows: Add 3.7 g/L NaHCO3 (Sigma) to DMEM with high glucose 
and supplemented with 1% non-essential amino acids, 1% sodium pyruvate, 0.1 
mM β-mercaptoethanol (β -ME), 1% penicillin/streptomycin (all from Invitrogen) 
and 10% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA) and 
maintained at 37 °C with 5% CO2. MEFs were then allowed to incubate for 24 
hours prior to transfection. For miRNA mimic/inhibitor transfection experiments, 
MEFs were plated at 20,000 cells/cm2 in MEF transfection medium which is 
identical to MEF expansion medium but containing 5% FBS rather than 10%. 
Mimic/inhibitor transfection was performed by first incubating RNAiMAX 
(Invitrogen) with either miR-297c mimic, miR-297c inhibitor, negative control 
mimic, negative control inhibitor or transfection reagent alone (all from Invitrogen) 
for 30 minutes in serum-free Opti-MEM® (Invitrogen) at 37 °C. Mimics/inhibitors 
were added to the MEF cultures already containing MEF transfection medium 
and allowed to incubate overnight. Transfection efficiencies were established to 
be 41.53% ± 15.67% (± standard deviation) with pilot experiments transfecting 
either FAMTM Dye-labeled pre- or anti-miR controls (Invitrogen) into MEFs thus 
allowing FACS-based assessment of FAM+ events relative to total events (Fig. 
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11). An Opti-MEM® alone condition was included to assess any effects from the 
transfection reagent alone. The following morning, a full media change with MEF 
transfection media was performed on all plates prior to being returned to the 
incubator for 24 additional hours. For cell cycle analysis, MEFs were collected 
from plates and fixed with ice-cold 70% ethanol (EtOH) for at least 48 hours at -
20 °C. A single plate is considered n = 1 and each condition was replicated to 
achieve n = 4 for qRT-PCR experiments.   
 
ICC. Cells were washed in DPBS and incubated with the appropriate hybridoma 
supernatant (A2B5, O4 or O1) diluted to 70% v/v in 20% DPBS, and 10% NDS 
for 45 minutes at 4 °C. Following washes (x3) with DPBS and fixed with 4% PFA 
at room temperature for 10 minutes. Cells were incubated overnight with 
additional primary polyclonal antibodies NG2 (rabbit, 1:500, Millipore, Billerica, 
MA), βIII-tubulin (rabbit, 1:2000, Covance, Princeton, NJ), MBP (rat, 1:100, 
Millipore), GFAP (rabbit, 1:500, Dako, Glostrup, Denmark) and Map2 (rabbit, 
1:100, Sigma) at 4 °C diluted in blocking solution containing 10% NDS, 0.5% 
BSA and 0.1% Triton X-100 in DPBS. The following morning, cells were washed 
(x3) with TBS and incubated with fluorescein (FITC; 1:200) or rhodamine (TRITC; 
1:200)-conjugated F(ab′)2 secondary antibodies (donkey, Jackson 
ImmunoResearch; West Grove, PA) for 1 h at room temperature. Species-
specific IgG isotype controls were used to account for any non-specific binding or 
other cellular protein interactions. Hoechst™ was used to identify nuclei. 
Photomicrographs were captured using a Nikon TiE 300 inverted microscope 
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with a DXM-1200C coded digital camera and NIS Elements software (Nikon, 
Melville, NY). Counts of monolayered cultured cells were performed in 5 
randomly chosen fields per culture dish well and percentages of A2B5+/Hoechst+, 
O4+/Hoechst+, O1+/Hoechst+ or GFAP+/Hoechst+ cells per total Hoechst+ nuclei 
were used for quantification. A one-way ANOVA was performed and data are 
presented as a mean percentage ± standard deviation. 
 
Cell Cycle Analysis. Following transfection, cells were washed (x2) with DPBS to 
remove serum containing media and harvested by trypsinization for 3 minutes at 
37 °C after which they were collected and diluted with MEF media containing 
10% FBS and centrifuged at 300 x g for 5 minutes. Following centrifugation, cell 
pellets were washed (x2) with DPBS to remove media and trypsin. Finally, the 
supernatant was aspirated and ice cold 70% ethanol (EtOH) was added to the 
cell pellets with gentle trituration and allowed to fix for at least 48 hours. 
Following fixation, cells were centrifuged at 300 x g for 5 minutes and washed 
(x2) with DPBS. Cells were then stained overnight with the DNA intercalator 
propidium iodide (PI) to assess DNA content. The following day, cells were 
analyzed with a 3-channel FACSCaliber flow cytometer (BD Biosciences 
Immunocytometry Systems, San Jose, CA). Data were exported as FCS files and 
further analyzed using Flowjo software (treestar.com). The G1/G0 and G2/M 
histogram peaks were fit to the Watson Pragmatic Model (Watson et al., 1987) 
and the G1/G0, S-phase and G2/M frequencies were quantified. Student t-tests 
were performed between mimic/inhibitor transfection group and transfection 
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control groups. A one-way ANOVA was performed and data are presented as 




CNP-EGFP+ cells sorted from callosal tissue display mRNA expression profiles 
highly consistent with that of OPs and not mature OLs or other CNS cell types.    
 
Animal weights were monitored weekly throughout the course of the experiment 
and any outliers were removed from the study. Outliers are defined as being ± 2 
standard deviations from the mean weight of all age matched mice. IHC 
confirmed that CNP-EGFP expression was specific to oligodendroglia and not 
other CNS cell types (Fig. 9A) and that cuprizone-induced de- and re-myelination 
within the corpus callosum was accompanied by a reduction and return of 
callosal CNP-EGFP expression, respectively (Fig. 9B,C).  
 
To confirm the lineage and developmental stage of CNPase+ cells, RNA isolated 
from sorted cells was screened with qRT-PCR to assess the expression levels of 
genes differentially expressed in OPs (Olig2 and PDFGRα; Fig. 10B), OLs (Olig2 
and MBP; Fig. 10B), astrocytes (GFAP; Fig. 10B), neurons (Map2; Fig. 10B) and 
myeloid lineage cells (CD45; Fig. 12B) relative to RNA isolated from an equal 
post-dissection volume of homogenized whole callosal tissue which contains 
RNA from all CNS cell types (Fig. 10B). Sorted naïve cells displayed robust 
99 
 
expression levels of Olig2 and PDGFRα, both genes highly expressed in 
oligodendrocytic progenitors (Fig. 10B). Although Olig2 is expressed in both OPs 
and mature myelinating OLs,  PLP2 and MBP (two genes specifically expressed 
in myelinating OLs) were not highly expressed in sorted cells suggesting an 
absence of mature OLs from sorted populations (Fig. 10B). This is not surprising 
as the dissection, digestion, and dissociation protocol combined with myelin layer 
removal is likely to have eliminated mature OLs from sorted populations. Other 
genes representative of non-oligodendroglial CNS cell types displayed low 
expression levels compared to whole tissue suggesting that there is little to no 
contamination from astrocytes (GFAP; Fig. 10B) or neurons (Map2; Fig. 10B) in 
sorted populations. All the data presented above has been in reference to naïve 
callosal OPs. Sorted callosal OPs following 6 weeks of cuprizone treatment 
displayed similar gene expression profiles for Olig2, PDGFRα, MBP, GFAP, 
Map2 and CD45, but PLP1 expression was significantly up-regulated in the 6 
week cuprizone group compared to the no cuprizone group (Fig. 10B). Using 6 
weeks on cuprizone RNA, no CD45+ cells were present when sorting with the 
IgG-perCP isotype control (gate R4; Fig. 12A) but a negligible number of 
CD45+/CNPase+ cells were identified using the CD45-perCP antibody 
representing  < 0.2% of sorted CNPase+ events (gate R4; Fig. 12B).  
 
Sfmbt2 cluster miRNAs were identified via microarray and share similar 




Bioanalyzer (Agilent Technologies, Santa Clara, CA) results provided by Exiqon 
revealed acceptable RNA quality for all samples. PCA demonstrated clustering of 
samples with other replicate samples from a given cuprizone treatment condition 
and segregation of clustered samples between cuprizone treatment conditions  
(data not shown). Out of 1,215 mouse miRNAs assayed in the microarray, 439 
miRNAs were identified as being present above background in each sample 
(regardless of cuprizone treatment condition) demonstrating consistency across 
cuprizone conditions but not accounting for abundance. Using group ANOVAs 
corrected for FDR, 237 miRNAs out of 439 changed significantly across 
cuprizone treatment conditions. A list was comprised a priori to assess if miRNAs 
identified in the microarray were consistent with oligodendroglial-derived or white 
matter-derived miRNAs previously identified in the literature (Fig. 13). There was 
no restrictive criterion to include a miRNA on the list in that it only needed to be 
loosely associated with oligodendroglia considering miRNAs identified in while 
white matter tissue were also included (Fig. 13). Overall, 38 miRNAs were 
included with sources ranging from human and rodent-derived oligodendroglia to 
human MS lesion tissue to human or rodent-derived Schwann cells (Fig. 13). Of 
the 38 miRNAs listed in Fig. 13, 34 (89%) were also identified via microarray with 
29 of the 34 miRNAs (85%) identified as changing significantly across cuprizone 
treatment conditions as per the group ANOVA (Fig. 13).  
 
No differences were identified between the 8 week and the 20 week no cuprizone 
groups. OP miRNA expression profiles are dynamically regulated during 
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cuprizone-induced demyelination (3 and 6 weeks on cuprizone) and 
remyelination (3 and 6 weeks off cuprizone; Fig. 14A). Moreover, despite the fact 
that the callosi of multiple age matched mice (both male and female) were pooled 
together to yield sufficient RNA quantities, the miRNA expression values across 
N’s of a particular cuprizone treatment condition were highly reproducible (Fig. 
14A). Regression analyses of the miRNA expression levels for all miRNAs 
between 2 samples of a given treatment condition were performed for all possible 
sample comparison combinations and revealed that all 3 samples in the no 
cuprizone, aged cuprizone, 3 weeks and 6 weeks on cuprizone groups had an R-
squared (R2) value of > 0.95, p < 0.001 (data not shown). This demonstrates that 
expression levels across samples within a particular group were highly consistent 
for the control, 3 and 6 weeks on cuprizone groups. Regression analyses of the 3 
week and 6 week off cuprizone groups revealed that one of the 3 samples in 
each group displayed R2 values of 0.59 and 0.80, respectively, while the other 2 
remaining samples in each group displayed R2 values of > 0.97, p < 0.001. 
Additionally, the 2 outlier samples were determined by principle component 
analysis to not cluster with the other respective samples in their group. 
Therefore, these samples were removed from statistical analysis. Mean miRNA 
expression levels analyzed across cuprizone treatment conditions were ordered 
by corrected P value. Over half of the top 25 most significant miRNAs were 
members of the Sfmbt2 miRNA cluster, a recently identified group miRNAs 
located within < 10 kb of each other on intron 10 or 11 of the Sfmbt2 host gene 
(Wang et al., 2011; Fig. 14A). Moreover, hierarchical clustering demonstrated 
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that 52 of 53 (98%) Sfmbt2 cluster miRNAs clearly segregated together into 3 
primary clusters representing 53% (cluster A), 42% (cluster B) and 83% (cluster 
C) of the miRNAs in each respective cluster (data not shown). Furthermore, 
clusters A and B were associated by a primary node and all 3 clusters were 
associated by a secondary node (data not shown). Fold change relative to the no 
cuprizone group was assessed for 3 and 6 weeks on and 3 and 6 weeks off 
cuprizone revealing that nearly all Sfmbt2 cluster miRNAs share a similar 
expression profile across cuprizone treatment conditions (Fig. 14B). In total, 53 
Sfmbt2 cluster miRNAs were identified in the microarray and each were 
determined to change significantly across cuprizone treatment conditions (group 
ANOVA corrected for FDR). All but one Sfmbt2 cluster miRNA (miR-466h) 
displayed a profile highlighted by a down-regulation of Sfmbt2 miRNAs at the 6 
week on cuprizone time-point (Fig. 14B). Post-hoc t-tests of Sfmbt2 cluster 
miRNAs revealed that the decrease in expression observed at 6 weeks was 
significant for each miRNA analyzed relative to no cuprizone (data not shown).  
 
Sfmbt2 cluster member miR-297c is up-regulated following differentiation of 
primary mouse OPs in vitro 
 
24 hours post-MACS isolation, 93.94% ± 6.84% of total Hoechst+ nuclei were 
also A2B5+ and 83.24% ± 9.35% were O4+ (± standard deviation; Fig. 15A,C). 
Following 72 hours of differentiation with mitogen removal and T3 addition to the 
culture medium, process elongation and arborization were accompanied by a 
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reduced percentage of A2B5+ to 14.87% ± 7.77% and O4+ cells 46.23% ± 7.77% 
relative to total Hoechst+ nuclei (Fig. 15C). Moreover, O1+ cells which were not 
present 24 hours post-MACS was identified following 72 hours differentiation 
constituting 41.88% ± 18.64% of total Hoechst+ nuclei (Fig. 15B,C). Antibodies 
raised against GFAP, an intermediate astrocyte filament, demonstrated GFAP+ 
immunoreactivity 24 hours post-MACS or following 72 hours proliferation to be 
1.54% ± 0.05% of total Hoechst+ nuclei (Fig. 15A,C). Following 72 hours of 
differentiation, GFAP expression increased to 27.50% ± 8.83% % of total 
Hoechst+ nuclei (Fig. 15B,C). This suggests that along the course of 
differentiation, approximately a quarter of the primary mouse OPs magnetically 
sorted with the O4 sulfatide begin to follow along an astrocytic lineage rather 
than maintain an exclusive oligodendrocytic lineage. This is typical of cultured 
mouse OPs considering their bi-potentiality. 
  
The expression profiles of multiple Sfmbt2 miRNAs as well as other miRNAs 
identified in the microarray were assessed during the differentiation of primary 
mouse OPs isolated from P5 mouse pup cortical tissue. The specific Sfmbt2 
cluster member miRNAs screened was determined based on either novelty, 
anomalous microarray expression profile or a target prediction profiles with high 
prediction scores for oligodendroglial transcripts. Although the microarray 
revealed a significant change as per the group ANOVA for miR-338-5’, post-hoc 
t-tests revealed that there was no change in miR-338-5’ expression at 3 weeks 
and 6 weeks on cuprizone relative to no cuprizone (data not shown). Our a priori 
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assumption was that miR-338-5’ would be up-regulated at 6 weeks on cuprizone 
considering that qTR-PCR experiments revealed increased PLP1 mRNA 
expression at 6 weeks on cuprizone compared to no cuprizone (Fig. 10B) but this 
was not observed. However, the lack of an increase in miR-338-5’ expression at 
6 weeks on cuprizone could be explained the possibility that sorted populations 
display an expression profile consistent with a progenitor phenotype (Fig. 10B) 
and miR-338-5’ was shown to increase concomitant with the expression of 
mature OL myelination genes (Dugas et al., 2010; Hu et al., 2010). Therefore, 
terminally committed oligodendroglia displaying increased miR-338-5’ were likely 
eliminated during the isolation protocol and do not contribute the RNA isolated 
from sorted cells. Moreover, although there is a significant increase observed in 
PLP1 mRNA at 6 weeks post-cuprizone, it is likely that in addition to proliferating 
OPs, sorted populations also contained terminally committed oligodendroglia in 
the very initial stages of remyelination. In this pool of cells, PLP protein 
production and myelination has not yet completed making them less susceptible 
to percoll removal thus representing a higher proportion of sorted populations 
thereby accounting for the increase on PLP1 expression. Although miR-338-5’ 
displayed no change in expression via the microarray, we still view it as an 
acceptable positive control to differentiation in vitro as it has been previously 
identified by Dugas et al. (2010) and Hu et al. (2010) to increase concomitant 
with OL differentiation. Consistent with what has been previously described, miR-
338-5’ was significantly increased in primary mouse OPs following 72 hours of 
differentiation compared to 72 hours of proliferation (Fig. 15D). Of all Sfmbt2 
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cluster miRNAs assayed, only miR-297c was significant, consistently displaying 
expression levels of 3 fold or higher in differentiating mouse OPs relative to 
proliferating mouse OPs (Fig. 15D).  
 
miR-297c regulates S-phase transition in cycling MEFs  
 
Three separate target prediction algorithms (miRDB, miRanda and 
TargetScanMouse) each predicted miR-297c to target the cyclin T2 (CCNT2) 
transcript with a high reliability score. Considering that CCNT2 has recently been 
described as a regulator of G1 to S-phase transition via its interaction with cyclin 
dependent kinase 9 (CDK9) in P-TEFb complex formation (Fig. 16A; Peng et al., 
1998; Price, 2000), miR-297c mimics and inhibitors were transfected into cycling 
MEFs to assess a role for miR-297c in G1 to S-phase transition using cell cycle 
analysis (Fig. 16B). Fig. 16 is a representative schematic of P-TEFb-induced G1 
to S-phase transition (Fig. 16A) and its possible miR-297c-induced repression 
(Fig. 16B). Cell cycle analysis revealed that 48 hours following miR-297c or 
control transfection, MEFs transfected with miR-297c displayed a significant 
increase in G1/G0 frequencies (Fig. 17A) and a significant reduction in S-phase 






The mRNA expression profile of sorted cells from naïve adult mice was highly 
consistent with that of an OP profile (Fig. 10B). Both Olig2 and PDGFRα 
transcripts were present within sorted populations in abundance. Olig2 is not 
considered here as a genetic identifier of OPs per se, but rather as a general 
genetic identifier of oligodendroglial cells at any developmental stage. Although 
the presence of Olig2 mRNA in sorted populations was robust, this does not 
distinguish between terminally committed OLs versus mitotically competent OPs.  
However, considering that MBP and PLP1 mRNA expression was minimal, this 
suggests that sorted populations were of a less mature phenotype. Furthermore, 
PDGFRα mRNA expression in sorted populations was robust which again 
suggests an immature phenotype. PDGFRα (CD140a) expression has been 
demonstrated to be specific to OPs in both rodent (Pringle et al., 1992; Ellison 
and de Vellis, 1994) and humans (Sim et al., 2006). Using CD140a based 
isolation of OPs from human tissue, PDGFRα expressing cells were shown to 
represent a subpopulation of OPs which favor an oligodendrocytic rather than an 
astrocytic fate (Sim et al., 2011). Therefore, the CNPase+ sorted OPs we report 
here most likely were destined to follow down an oligodendroglial lineage and 
thus mRNA expression profiles are representative of OPs already committed to 
become oligodendrocytes rather than truly bipotential OPs. Although other CNS 
cell types are also present in the sorted population, low GFAP and Map2 
expression suggests that their contribution to total RNA pools was minimal and 
that their numbers in sorted populations were few making the purity of sorted 




The significant increase in PLP1 expression following 6 weeks on cuprizone 
compared to no cuprizone (Fig. 10B) is not surprising as PLP1 mRNA has been 
identified in developing and adult mouse NG2+ OPs (Ye et al., 2003). Within the 
6 week compared to the no cuprizone corpus callosum, there are likely higher 
proportions of OPs which have not only terminally committed to an 
oligodendroglial fate but are in or nearing the pre-myelinating stage and therefore 
do not yet express mature myelin. Therefore, unlike their mature myelinating 
counterparts, these pre-myelinating oligodendroglia would be less sensitive to 
disruption from either digestion or dissociation increasing their proportion in 
sorted populations thus inflating PLP1 transcript levels in RNA from sorted 
populations.  
 
Inflammation within the corpus callosum is observed following 6 weeks of 
cuprizone (Buschmann et al., 2012). Although CNPase is enriched within 
oligodendroglia, it has also been suggested to be present in reactive microglia 
(Wu et al., 2006). Although CNPase+/CD45+ cells were present in sorted 
populations, their contribution was negligible, < 0.20% of total sorted events. 
Interestingly, there was also a small subset of CNPase-/CD45+ cells which are 
likely representative of systemic inflammatory cells that have infiltrated the 




The high percentage of miRNAs listed in Fig. 13 which are also expressed in the 
microarray strongly suggests that the miRNA expression profile of sorted 
populations is consistent with what has been previously described for 
oligodendroglial miRNAs. Sorted OPs displayed dynamically regulated miRNA 
expression profiles during cuprizone de- and re-myelination (Fig. 14A). Moreover, 
despite the fact that the callosi of multiple age matched mice (both male and 
female) were pooled together to yield sufficient RNA quantities, the miRNA 
expression values across Ns of a particular cuprizone treatment condition were 
highly reproducible (Fig. 14A). Included in the most significantly changed 
miRNAs are multiple members of the intrionic miRNA cluster located within the 
Sfmbt2 host gene (Fig. 14A,B). Nearly all Sfmbt2 cluster miRNAs identified in the 
microarray display a significant fold decrease (post-hoc t-test) in expression at 6 
weeks on cuprizone. Sfmbt2 is a polycomb-group gene that when translated into 
protein, forms an interaction with the transcription factor ying yang 1 (YY1; 
Kuzmin et al., 2008), an important regulator of both OP (He et al., 2007) and 
Schwann cell differentiation (He et al., 2011). Sfmbt2 is also a host gene for a 
cluster of miRNAs located within < 10 kb of each other on intron 10 or 11 of the 
Sfmbt2 host gene (Wang et al., 2011). Certain Sfmbt2 cluster miRNAs have been 
identified in past studies to regulate cell cycle. Leone et al. (2011) recently 
demonstrated that Sfmbt2 cluster member mmu-miR-297a binds within the 3’ 
untranslated region (UTR) of cyclin D2 (CCND2) transcripts thus negatively 
regulating CCND2 protein levels in thyroid cells in vitro. Human miR-297 was 
toxic to multiple glioblastoma cell lines with no effect on normal astrocytes 
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suggesting that it is a negative regulator of tumor cell proliferation (Kefas et al., 
2013). The Sfmbt2 cluster members mmu-miR-466h-5’ and mmu-miR-669c were 
both identified to negatively regulate several anti-apoptotic genes in unison 
following glucose deprivation-induced oxidative stress (Druz et a., 2011). Using 
RISC-immunoprecipitation following miRNA transfection, others have 
demonstrated that mmu-miR-466d-3’ binds to cyclin B1 (CCNB1) transcripts in 
the CCNB1 promoter (Huang et al., 2012). However, rather than negatively 
regulating CCNB1 translation, mmu-miR-466d-3’ transfection induced CCNB1 
protein expression while knockdown repressed CCNB1 protein levels (Huang et 
al., 2012). This paradoxical effect is not unprecedented as others have 
suggested a possible role for miRNAs in translation induction when binding to 
their targets within the 3’ UTR of promoter regions (Vasudevan et al., 2007; 
Rusk, 2008), however this effect is still not completely understood and reported 
instances are rare proportional to the breadth of studies demonstrating a clear 
role for miRNAs in translational repression. Nearly all Sfmbt2 cluster miRNAs 
identified in the microarray displayed a robust decrease in expression at 6 weeks 
on cuprizone relative to no cuprizone (Fig. 14B). Using a customized qRT-PCR 
array screen, Hibbets et al., (2012) demonstrated that the microenvironment 
present within the corpus callosum at 6 weeks cuprizone contains highly elevated 
levels of the OP mitogen FGF2 (Hibbits et al., 2012). Taken together, the 
elevated callosal FGF2 levels at 6 weeks cuprizone and corresponding 
decreased microarray expression of a miRNA cluster known to negatively 
regulate proliferation at 6 weeks on cuprizone suggests that the Sfmbt2 miRNAs 
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may normally repress proliferation but following an increase in mitogenic 
signaling via FGF2, these miRNAs are down-regulated to accommodate the 
translation of proteins required for cell cycle entry. 
 
As validation that Sfmbt2 miRNAs regulate OPs, multiple Sfmbt2 miRNAs were 
screened with qRT-PCR following RNA isolation from primary mouse OPs 
allowed to differentiate or proliferate for 72 hours in vitro. One Sfmbt2 cluster 
member screened, mmu-miR-297c (miR-297c), was found to significantly 
increase concomitant with differentiation (Fig. 15D). Moreover, oligodendroglial 
enriched miRNA miR-338-5’, previously shown to increase during 
oligodendroglial development in vivo (Zhao et al., 2010) and in vitro (Dugas et al., 
2010; Zhao et al., 2010), was also significantly up-regulated in differentiating 
cells compared to proliferating OPs (Fig. 15D) thus serving as a positive control 
to mouse OP differentiation. Using the miRanda software, miRNA and target 
transcript alignment revealed that miR-297c targeted CCNT2 in at least 3 
different miRNA binding regions on the CCNT2 transcript. One miR-297c binding 
region overlapped with the binding region of multiple other Sfmbt2 cluster 
miRNAs suggesting that many of the miRNAs within that cluster may not only 
regulate the same transcripts, but at the same binding region on the target 
transcript. Moreover, the oligodendroglial specific miRNAs miR-23a and miR-
338-5’ which have been previously described to regulate oligodendroglial lineage 
cells, were both predicted by the miRDB algorithm to target the CCNT2 
transcript. This suggests that miR-297c, miR-23a and miR-338-5’ may play 
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similar roles and share similar expression profile changes during differentiation 
and this is consistent with what we report here (Fig. 15D). CCNT2 is the 
regulatory subunit of P-TEFb, a complex formed by both CCNT1/2 proteins and 
cyclin dependent kinase 9 (CDK9; Kohoutek, 2009; Fig. 16A). Once formed, P-
TEFb can then interact with Bromodomain-containing protein 4 (BRD4) which 
recruits a now active P-TEFb to G1 genes, a necessary step for G1 to S-phase 
transition (Kohoutek, 2009; Fig. 16A). Therefore, increased miR-297c expression 
and subsequent repression of CCNT2 translation may prevent P-TEFb complex 
formation thus limiting S-phase transition resulting in G1/G0 cell cycle arrest (Fig. 
16B). As miR-297c was described by 3 separate algorithms to target CCNT2 
mRNA, we see this as a likely mechanism by which miR-297c regulates cell 
cycle entry (Fig. 16). 
 
To assess the hypothesis presented in Fig. 16, MEFs were transfected with one 
of the following: miR-297c mimic, miR-297c inhibitor, negative control or 
transfection reagent alone and cell cycle analysis was performed with PI. The 
Sfmbt2 cluster member miR-669i was determined in pilot studies to not change 
during primary OP differentiation and was therefore included as a Sfmbt2 miRNA 
internal control (Fig. 17). The most likely cell cycle effect of reducing P-TEFb 
activation via repression of CCNT2 translation would be a reduction in S-phase 
cells and an increase in G1/G0 cells and this is consistent with data reported here 
(Fig. 17A,B). The fact that gain and loss of function assays for miR-297c were 
performed in MEFs rather than primary OPs or an oligodendroglial cell line does 
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not preclude miR-297c from being considered as a regulator of other non-MEF 
mouse cells. Cell cycle genes are highly conserved across species and will 
certainly maintain high homology within different cells of the same organism. 
Therefore, whether or not miR-297c itself is normally present in MEFs is 
irrelevant as CCNT2 transcripts are equally as susceptible to regulation by 
exogenously applied miR-297c as they are to endogenous miRNAs.   
 
In conclusion, Sfmbt2 miRNAs are dynamically regulated during cuprizone-
induced de- and re-myelination. Here, we report the first evidence of a role for 
the Sfmbt2 cluster member miR-297c in cell cycle control. This is but one of 
many studies which establish a role for miRNAs in cell cycle control (Wang and 
Blelloch, 2009; Chen and Hu, 2012; Malhas et al., 2010). However, this is the 
first documentation of miRNAs regulating cell cycle in oligodendroglia isolated 
from an in vivo source. Cell cycle progression in OPs is dependent on FGF2- and 
insulin-like growth factor 1 (IGF-1)-induced cyclin D1 protein production 
(Frederick and Wood, 2004; Frederick et al., 2007). Furthermore, promoting OP 
cell cycle exit by mitogen removal has been described as a potent inducer of OL 
differentiation (Casaccia-Bonnefil and Liu, 2003; He et al., 2007). Therefore, it is 
not surprising that miR-297c, which we have demonstrated here to increase 
concomitant with OP differentiation, also resulted in the cell cycle arrest when 
transfected into cycling cells. Together, these results suggest that strategies 
aimed at augmenting miR-297c expression in OP grafts prior to transplantation 
may favor oligodendrocytic differentiation thus promoting an optimal proportion of 
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oligodendrocytes to astrocytes during remyelination. On the other hand, 
pharmacological strategies aimed at reducing miR-297c levels during 
endogenous remyelination may enhance the proliferative response of 
endogenous OP pools during remyelination ultimately providing more mature 
OLs and thus more remyelination. Further investigation is necessary to 
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Figure 9. Oligodendroglial CNPase-EGFP+ reporter expression facilitates the 
quantification of cuprizone-induced de- and re-myelination. Endogenous 
CNPase-EGFP+ reporter expression identifies oligodendroglial lineage cells 
within brain white matter (A) while not co-localizing with GFAP (B) or NF-M (C). 
Callosal CNPase-EGFP+ reporter intensity was analyzed in selected ROIs (D, E 
and F) following no cuprizone (D), 6 weeks on cuprizone (E) or 6 weeks off 
cuprizone (F). Intensity levels above background were quantified (G) revealing 
significant loss of callosal CNPase-EGFP+ expression at 6 weeks on cuprizone 
(E and G) which returned by 6 weeks off cuprizone (F and G). Data in G are 
presented as mean ± standard deviation; *p < 0.05, **p < 0.001. Scale bars in A, 
























Figure 10. FACS-based isolation of callosal CNPase-EGFP+ yields a cell 
population with mRNA profiles highly consistent with OPs. A bright EGFP+ cell 
population (gate R3; A) was consistently present above background in all 
samples and was 52.34% ± 7.45% (± standard deviation) of total sorted events 
(gate R1; A). qRT-PCR of sorted OPs demonstrated a high proportion Olig2 and 
PDGFRα transcripts relative to whole corpus callosum (B). Transcripts typically 
expressed in maturing oligodendroglia (MBP and PLP1) were not identified in 
sorted cell populations relative to whole corpus callosum (B). Map2 (B) and 
GFAP (B) transcripts were also not identified in sorted populations suggesting a 
highly oligodendroglial phenotype. Following 6 weeks of cuprizone, sorted OPs 
displayed a significant increase in PLP1 mRNA expression compared to no 
























Figure 11. Transfection of FAMTM Dye-labeled pre- or anti-miR scrambled RNA 
controls into MEFs for FACS-based assessment of FAM+ events. FAM+ intensity 
from MEFs transfected with a pre- or anti-miRNA negative control was used to 
adjust threshold parameters (A). FAM+ events relative to total events were 
calculated in real time with transfection efficiencies of 41.53% ± 15.67% across 
































Figure 12. Sorted CNPase-EGFP+ populations are not contaminated by myeloid 
lineage cells. Using callosal RNA isolated from mice following 6 weeks on 
cuprizone, no CD45+ cells were present when sorting with the perCP+ conjugated 
antibody (gate R4; A). IgG-perCP isotype control expression was used to set 
threshold parameters (A). A negligible number of CD45+/CNPase+ cells were 
identified using the CD45-perCP antibody representing  < 0.2% of sorted 
CNPase+ events (gate R4; B). A subset of CD45+/CNPase- cells were also 





























Figure 13. Table of miRNAs identified in the microarray also consistent with 
oligodendroglial-derived or white matter-derived miRNAs previously identified in 
the literature. List was comprised a priori and miRNAs only needed to be loosely 
associated with oligodendroglia. As miRNAs identified in while white with 
techniques that do not account for cell specificity, this list is representative of 
miRNAs with the potential to be oligodendroglial rather than oligodendroglial-
































Figure 14. Microarray data reveals that Sfmbt2 cluster miRNAs are significantly 
decreased at 6 weeks on cuprizone compared to no cuprizone miRNA 
expression levels. A Z-score heat map displaying the number of standard 
deviations a particular miRNA’s expression is from the mean expression of all 
mIRNAs identified above background in the microarray (A). OP miRNA 
expression profiles are dynamically regulated during cuprizone-induced 
demyelination (3 and 6 weeks on cuprizone; A) and remyelination (3 and 6 
weeks off cuprizone; A). Pooled samples displayed consistent miRNA expression 
values across samples of a particular cuprizone treatment condition (A). Over 
half of the top 25 most significant miRNAs were members of the Sfmbt2 miRNA 
cluster, a recently identified group of miRNAs located within intron 10 or 11 of the 
Sfmbt2 host gene (A). Fold change relative to the no cuprizone group was 
assessed for 3 and 6 weeks on and 3 and 6 weeks off cuprizone revealing that 
nearly all Sfmbt2 cluster miRNAs share a similar expression profile across 































Figure 15. Sfmbt2 cluster member miR-297c displays a significant increase 
concomitant with differentiation in primary OPs. 24 hours post-MACS isolation, 
93.94% ± 6.84% of total Hoechst+ nuclei were also A2B5+ (C) and 83.24% ± 
9.35% were O4+ (A and C). Following 72 hours of differentiation with mitogen 
removal and T3 addition to the culture medium, process elongation and 
arborization were accompanied by a reduced percentage of A2B5+ to 14.87% ± 
7.77% (C) and O4+ cells 46.23% ± 7.77% (C) relative to total Hoechst+ nuclei. 
O1+ cells were not present 24 hours post-MACS (C) but were identified following 
72 hours differentiation constituting 41.88% ± 18.64% of total Hoechst+ nuclei (B 
and C). Antibodies against GFAP, an intermediate astrocyte filament, 
demonstrated GFAP+ immunoreactivity 24 hours post-MACS or following 72 
hours proliferation to be 1.54% ± 0.05% of total Hoechst+ nuclei (A and C). 
Following 72 hours of differentiation, GFAP expression increased to 27.50% ± 
8.83% of total Hoechst+ nuclei (B and C). As a positive miRNA control to 
differentiation, miR-338-5’ was assessed and demonstrated to be significantly 
increased in primary mouse OPs following 72 hours of differentiation compared 
to 72 hours of proliferation (B and D). Of all Sfmbt2 cluster miRNAs assayed, 
only miR-297c was significant, consistently displaying expression levels of 3 fold 
or higher in differentiating mouse OPs relative to proliferating mouse OPs (D). 
Data in D are presented as mean ± standard deviation; *p < 0.05. Scale bars in A 















Figure 16. miR-297c transfection regulates cell cycle progression in MEFs. 
Multiple target prediction algorithms predicted miR-297c to target the cyclin T2, a 
regulator of G1 to S-phase transition. Provided is a mechanistic schematic of 
potential regulatory control of cell cycle by miR-297c induction. Normally in 
mitotic cells, cyclin T and CDK9 form a complex (P-TEFb) which can then 
interact with BRD4 which promotes P-TEFb recruitment to G1 genes thus 
favoring G1 to S-phase transition (A). Following induction of miR-297c, cyclin T 







































Figure 17. miR-297c regulates S-phase transition in cycling MEFs. Cell cycle 
analysis revealed that 48 hours following miR-297c or control transfection, MEFs 
transfected with miR-297c displayed a significant increase in G1/G0 frequencies 
(A) and a significant reduction in S-phase frequencies (B). Data in A and B are 























The dogmatic idea that CNS damage results in permanent cell loss and chronic 
dysfunction or death has existed for thousands of years, even dating back to 
Egyptian times (Eltorai, 2003). Only in the last several decades have we begun 
to understand the regenerative potential of the CNS, which is not equal in all cell 
types and often remains incomplete (Silver, 2009). There are several neurogenic 
niches in the adult mammalian CNS which harbor mitotically competent cells able 
to respond to cell loss by replicating themselves, migrating to the site where they 
are needed, differentiating into one of many CNS cell types and finally integrating 
back into the CNS (Horner and Gage, 2000). As the focus of this manuscript is 
oligodendroglial lineage cells, further discussion concerning regeneration and 
functional recovery will be from the perspectives of remyelination and 
demyelination, respectively. The regenerative potential of white matter is actually 
rather incredible. CNS myelinogenesis continues well after birth with ongoing 
oligodendroglial development demonstrating the highly dynamic and plastic glial 
environment (Dubois et al., 2013). Additionally, there is simultaneous turnover of 
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the already mature OLs which are constantly being replaced by resident OPs. 
This process proceeds without limitation during normal myelin maintenance 
(Young et al., 2013). However, following trauma- or disease-induced 
demyelination, the number of axons which lack myelin is too great and OPs are 
not available in the quantities required for complete remyelination. As a result, 
the dysfunction associating with demyelination is never fully restored and persists 
chronically. This highlights the importance of research attempting to enhance 
remyelination when the endogenous regenerative response is sub-optimal.   
 
The Modalities of Demyelination 
 
The data presented in Chapters 2 – 4 demonstrate that demyelination is 
accompanied by complex and widespread changes at both the whole organism 
level (Chapters 2 and 3) and at the molecular level (Chapter 4). These disease-
oriented changes manifest as multiple modalities. Behavioral dysfunction, tissue 
loss (axonal and glial), cellular changes and compromised molecular events are 
all major components of the post-demyelination sequelae but ultimately they 
cannot be individualized as there is a connectivity present between all of these 
modalities which ultimately manifests as disease pathology. Although the 
complexity and interworking of that interconnectivity are not completely 
understood, it is safe to assume that until all are ameliorated, remyelination will 
not be complete. Most therapeutic remyelination strategies target only one of 
these modalities. This is not out of ignorance as experimentally evaluating more 
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than one of the above mentioned issues begins to introduce too many variables, 
making experimental results difficult to interpret thus compromising parsimony. 
When only a single variable is manipulated, and assuming experimental design is 
acceptable, parsimony will be maintained. So the question stands, “Is it non-
parsimonious to simultaneously approach an experimental design from 
modalities ranging from behavior for molecular biology?” It may be. However, it 
must also be considered that the most effective experimental design to wholly 
address a complex, multi-factorial disease such as demyelination, may not be the 
most parsimonious.  
 
Studies maintaining maximal parsimony which perform few manipulations and 
focus on two or less modalities, are crucial to understanding particular 
fundamental aspects of oligodendroglial biology and the biology of all cell types 
involved in remyelination for that matter. Even the experiments detailed here in 
Chapters 2 – 4 were completed using limited modality experimental designs. But 
rather than attempting to translate a single treatment strategy from bench to bed-
side entirely within one modality, it may be more advantageous to combine 
multiple treatment strategies from across different modalities (i.e. manipulating 
the molecular landscape of cells, manipulating the identity of populations of cells, 
manipulating the host environment prior to and following transplantation to 
promote survival, transplanting cells to replace lost tissue, managing immune 
rejection concerns and providing training /rehab and physical therapy to facilitate 
these newly transplanted cell’s integration into the CNS). Therefore, there is a 
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need for studies which combine multiple treatment strategies all previously 
demonstrated to be effective on their own into the same model of demyelination. 
The hope would be that an additive or synergistic effect for remyelination would 
be observed thereby maximizing recovery.  
 
Treating Demyelination Clinically 
 
Treating demyelination so that lost function is completely restored is an arduous 
task. In fact to date, despite the wealth and breadth of data demonstrating 
successful remyelination in experimental models, no treatment currently exists 
where the patient’s cognitive ability, motor and sensory function, financial burden 
and overall quality of life were all restored to pre-injury levels following treatment. 
This does not take away from the incredible advancements which have been 
made both experimentally and clinically, but rather points out that despite all of 
the progress, we are still very far from a complete “cure”. Moreover, this 
phenomenon is not exclusive to the demyelinating disorders as no single “cure” 
is available clinically for any neurological condition, including but not limited to: 
SCI and TBI (from non-myelinogenic perspectives), Parkinson’s, Alzheimer’s, 
Huntington’s, amyl lateral sclerosis (ALS) as well as all of the genetic and 
acquired demyelinating disorders. Concerning neurological disease in general, 
progress has not been absolutely absent however as treatment options which 
slow disease progression and manage symptomology are available for other 
non-myelinogenic disorders of the CNS. For example, remarkable progress has 
136 
 
been made in the field of SCI (a traumatic event involving demyelination) where 
epidural stimulation of the spinal cord below the level of the lesion resulted in 
substantial functional recovery in patients with otherwise very poor prognoses 
(Harkema et al., 2011). However, the nature of this recovery is independent of 
remyelination as there is no documented evidence suggesting a link between 
rehabilitation / physical therapy and remyelination. Thus, treatment options for 
the myelinogenic disorders remain very limited with the development of a true 
“cure” being even more elusive.   
 
The mere idea of a true ”cure” for any neurological disease may be naïve as 
there may be no single therapeutic strategy which will completely “cure” an 
otherwise chronic CNS insult. As mentioned above, demyelination is 
accompanied by complex and widespread changes at both the whole organism 
and the molecular level. This brings up two important considerations: 1. such 
widespread changes may be too dramatic and disruptive for complete 
remyelination to occur making any attempts at recovery a futile pursuit; 2. in 
cases where there is at least some capacity for remyelination, it also needs to be 
considered that there is a limit to the extent of remyelination possible. The extent 
of remyelination possible would be determined by the cause of and extent of 
demyelination. In both cases, unless progress is attempted under the assumption 
that complete remyelination is achievable, understanding when a pursuit is futile 
and becoming aware of the existence of and limitations provided by such a 




There are multiple treatment options which are hopeful for the treatment of 
demyelination but they can essentially be arranged into two categories: 1. using 
pharmacological-based methods to enhance the endogenous remyelination 
response; 2. transplanting OPs into the demyelinated white matter in order to 
augment remyelination. Targeting endogenous OPs pharmacologically in an 
effort to facilitate remyelination by favoring oligodendroglial versus astroglial 
differentiation has some promise as a treatment for demyelination as it would 
accomplish the following: Limit astrogliosis (an inhibitor of remyelination) and 
provide more myelinating OLs. However, although shifting the 
astrocyte:oligodendrocyte ratio of transplanted cells to favor oligodendroglial 
differentiation would most likely provide some benefit to remyelination, the 
primary issue of too few OPs present still remains.  
 
Targeting endogenous OPs with treatments which would enhance their 
proliferation and the overall numbers available for remyelination could possibly 
improve the number of cells available in progenitor pools for remyelination. 
However, manipulating proliferation may also be accompanied by potentially fatal 
contraindications. For example, increasing proliferation in an already mitotically 
competent cell population may favor the in vivo selection of cells with a greater 
proliferative capacity. This capacity for proliferation may also be biologically 
synonymous with a capacity for tumorigenicity. When considering that 
glioblastomas (the most invasive form of brain cancer) are the result of aberrantly 
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cycling OPs, it may be unwise to pursue any treatment option clinically where 
enhanced proliferation is the ultimate goal as it would be unsafe and 
irresponsible to patients. Another possible side effect would be that the majority 
of the newly formed OPs would favor an astrocytic fate and ultimately contribute 
to glial scaring providing a barrier to remyelination. In both cases, 
pharmacologically targeting OPs to enhance proliferation fails to result in 
improved remyelination and may actually result in a poorer outcome that no 
treatment at all.  
 
Of all the options to improve remyelination mentioned above, the most realistic is 
cell transplantation. As detailed in Chapter 1, there are multiple potential sources 
for engrafted cells which can be transplanted into demyelinating lesions. The 
limited availability of both fetal and adult tissue has eliminated the possibility of 
using these tissues as a reliable source of OPs for clinical purposes. As a result 
the field has shifted to deriving OPs from human ES (hES) and induced 
pluripotent stem (iPS) cell sources. Both obviate the need for an OP source that 
is limitlessly scalable for any experimental and/or clinical purposes. However, 
iPS-derived OPs in culture exhibit much less teratoma formation than hES-
derived OPs and can be generated from the graft recipient. Additionally, human 
iPS cell-derived OPs reach senescence more rapidly that hES cell-derived OPs 
which reduced the time and resources involved with scalable expansion 
protocols. These two advantages make iPS cell-derived OPs the superior option 
for transplantation compared to ES or tissue-derived OPs. Moreover, prior to this 
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being adopted in clinics nationwide as a means to treat demyelination, much 
more stringent differentiation protocols must be established and flawless 
purification techniques must be attainable for both hES and iPS cell-based 
approaches. When considering that it may only take a single abhorrently 
proliferating transplanted cell to result in tumor replication and that the host 
immune system will already be compromised due to graft-promoting 
immunosuppression, these technical considerations are of the utmost 
importance. Until that time, OP transplantation in the clinic may remain absent. 
 
Even if transplantation strategies are used, this does not address all of the 
different dysfunctional modalities involved in demyelination. Remyelination by 
way of transplantation may also require a combinatorial approach where cell 
replacement strategies which replace lost tissue must be combined with at least 
rehabilitation and physical therapy to promote integration into the CNS. Cell 
transplantation strategies must maximize the volume of tissue restored while 
rehabilitation strategies and physical therapy must facilitate integration of the 
newly transplanted cells into the dysfunctional CNS making it indistinguishable 
from normal CNS tissue. Therefore, aside from attempting to optimize both 
transplantation- and rehabilitation-based treatment options, a more concerted 
effort needs to be made to combine treatments across multiple modalities in a 
single patient to assess the potential synergistic effects of such approaches. 
More importantly these strategies may maximize the patient’s chance at an 




miRNAs as Therapeutic Targets: Prospective Treatment Strategies for 
Demyelination 
 
The small size of miRNAs allows a single miRNA to target multiple mRNAs (Hu 
et al., 2012). The implications of this unique biological characteristic are that 
widespread effects on translation and ultimately cellular function can be achieved 
by a drug which introduces or inhibits expression of one to several miRNAs. This 
makes them attractive therapeutic targets as manipulating a single miRNA could 
regulate translation of multiple signaling molecules in a pathway as well as 
multiple signaling molecules in multiple pathways. In the case of demyelinating 
disease, as demonstrated in Chapter 4, oligodendroglial miRNA dysregulation 
accompanies demyelination. Identifying those miRNAs which are dysregulated 
may be advantageous to the development of treatments which aim to restore 
aberrant miRNAs to normal levels thus providing therapeutic benefit.  
 
A variety of in vivo methods have been described for the delivery of miRNAs or 
molecules to inhibit them (Hu et al., 2012). Intranasal administration of an anti-
miR-126 molecule conjugated to cholesterol successfully treated respiratory 
disease in mice by negatively regulating T-helper-2 cytokine production (Mattes 
et al., 2009). Others have delivered antisense oligonucleotide against miR-122 
(anti-miR-122) systemically in mice finding that it reduced miR-122 levels 
resulting in a therapeutic benefit in obese mice (Esau et al., 2006). Furthermore, 
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in vivo administration of lentiviral miR-26a inhibited nasopharyngeal 
tumorigenicity in nude mice (Lu et al., 2011). Moreover, systemically delivering 
miR-16 slowed metastatic prostate tumor growth by down-regulating multiple 
target mRNAs involved in cell cycle control thus preventing the translation of 
multiple cell cycle proteins translation in a xenograft model (Takeshita et al., 
2010). Although experimental progress has been promising in animal models, 
clinical trials are necessary to understand what potential there is for miRNA 
manipulation in human demyelination (Kasinski and Slack, 2011). 
 
Exosomes have also been suggested to be an efficient means of miRNA 
delivery. Due to their ability to efficiently shuttle small molecules between cells, 
exosomes are an extremely promising therapeutic tool for numerous diseases. 
Exosomes have been demonstrated to target specific cell types. Exosomes 
loaded with synthetic miRNA (siRNA) targeting Gapdh were injected into mice, 
Gapdh was specifically knocked down in the appropriate cell types, including 
neurons, microglia and OLs (Alvarez-Erviti et al., 2011). With the technological 
advances made in the field of exosomal biology, we are currently able to 
manipulate the contents within the exosome to deliver miRNAs favorable to 
remyelination. Moreover, it is also possible to manipulate the exosomal 
membrane proteins thus allowing for the cell-specific targeting or miRNA 
contents to areas of demyelination. For instance, exosomes engineered so that 
the PDGFRα binding domain of PDGFα is membrane bound and extracellularly 
exposed, exosomes with a miRNA payload favorable to remyelination could be 
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delivered to PDGFRα expressing OPs intrathecally, within a demyelinating lesion 
or even systemically. Of all delivery methods available for miRNA manipulations, 
exosomal-based miRNA delivery methods have the most promise in clinical trials 
because of the potential for tissue specificity and safety of exosomal use in 
humans (Hu et al., 2012).   
 
As mentioned in Chapter 1 and here in Chapter 5, when attempting to completely 
restore lost myelin to pre-demyelination levels, any strategy to enhance 
remyelination should begin with the transplantation of OPs into the demyelinated 
lesion. However, data presented in Chapter 4 demonstrates that demyelination is 
also accompanied by global miRNA dysregulation. Therefore, the manipulation of 
miRNAs to enhance remyelination should be applied in conjunction with OP 
transplantation. The most logical platform to achieve this would be an ex vivo 
approach where miRNAs or miRNA inhibitors are introduced into the OPs prior to 
engraftment. One group recently demonstrated that following tail veil injection of 
macrophages that have been manipulated ex vivo to express miR-143, miR-143 
was detectable in blood and cerebrospinal fluid (CSF; Akao et al., 2011). These 
data suggest that ex vivo approaches might carry much promise for the 
introduction of miRNAs favorable to remyelination in OPs prior to transplantation 
into a demyelinated lesion.  
 




There are currently 178 clinical trials listed involving miRNAs (clinicaltrials.gov). 
However, none of them are evaluating miRNA manipulation as a therapy. Rather, 
studies are focused on either gathering tissue to identify intracellular miRNA 
dysregulation from patient derived sources or attempting to detect miRNA levels 
in blood, cerebrospinal fluid (CSF) and from tissue biopsies for use as a 
diagnostic tool (Ciesla et al., 2011). With respect to the diagnostic potential of 
miRNAs, aberrant miRNAs have been identified in multiple diseases (Taylor and 
Gercel-Taylor, 2008; Rabinowits et al., 2009). The source of these miRNAs is 
exosomes released endogenously from diseased cells. Exosomes from diseased 
cell have miRNA expression profiles which are distinct from normal cell exosomal 
miRNA expression profiles. Eventually, these exosomes ultimately make their 
way to blood or CSF and are released allowing for their detection. Although 
several clinical trials have shown that miRNAs can be diagnostic tools for 
neurological disease, no diagnostic miRNAs have been identified in patients with 
a demyelinating disease.  
 
Additionally, rather than look at miRNA manipulation directly as a treatment 
option, we can use them to develop targets to demyelinating disease. In addition 
to data presented in Chapter 4, oligodendroglial miRNA dysregulation has been 
described in the molecular sequelae underlying demyelination in adult-onset 
autosomal dominant leukodystrophy (ADLD; Lin and Fu, 2009). It is likely that 
oligodendroglial miRNA dysregulation plays a role in most if not all demyelinating 
diseases. Therefore, determining differences in miRNA expression in patients 
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with a demyelinating disorder compared to the normal population, may reveal 
dysregulated miRNAs that play a crucial role in demyelination. The mRNA 
targets of those miRNA and their biological function in disease pathology can be 
determined experimentally thereafter allowing for the development of treatment 
strategies which may or may not involve miRNAs. 
 
Summary and Final Thoughts 
 
Here we present a comprehensive demonstration of the behavioral, systems-
level, cellular and molecular dysfunction associated with demyelination. Although 
current treatment options do not show substantive efficacy, there is much 
promise on the horizon for remyelination therapeutics as biological and 
technological advances have allowed for the development of OP transplantation-
based strategies and miRNA-based strategies, respectively. Whichever 
therapeutic strategy(s) is employed, it is imperative that it is done early. Certainly 
there is most likely a window that could be considered too early and intervening 
before this point would be detrimental. However, as described in Chapter 1, OLs 
have an important role in axonal health. Following demyelination, as an axon 
remains demyelinated, the lack of oligodendroglial support will continue. It is 
inevitable that a chronic removal of glial-derived axonal support will ultimately 
reduce axon viability if not resulting in axon loss. Moreover, axon loss has been 
documented following chronic demyelination (Lovas et al., 2000). Therefore, the 
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earliest intervention that can be responsibly and safely made must be attempted 
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